MXPA06002118A - Pyrimidothiophene compounds - Google Patents
Pyrimidothiophene compoundsInfo
- Publication number
- MXPA06002118A MXPA06002118A MXPA/A/2006/002118A MXPA06002118A MXPA06002118A MX PA06002118 A MXPA06002118 A MX PA06002118A MX PA06002118 A MXPA06002118 A MX PA06002118A MX PA06002118 A MXPA06002118 A MX PA06002118A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- group
- compound
- formula
- phenyl
- Prior art date
Links
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 143
- 101700042119 HSP83 Proteins 0.000 claims abstract description 62
- 101710023137 HSP90B1 Proteins 0.000 claims abstract description 61
- 101710006465 MOD-E Proteins 0.000 claims abstract description 60
- 101700017615 HSP82 Proteins 0.000 claims abstract description 59
- 230000000694 effects Effects 0.000 claims abstract description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 47
- 239000001257 hydrogen Substances 0.000 claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 23
- 125000001424 substituent group Chemical group 0.000 claims abstract description 19
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 12
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims abstract description 11
- 150000001733 carboxylic acid esters Chemical group 0.000 claims abstract description 10
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000000565 sulfonamide group Chemical group 0.000 claims abstract description 8
- 125000005418 aryl aryl group Chemical group 0.000 claims abstract description 4
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- -1 hydrate Substances 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 66
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000005842 heteroatoms Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- TVIVIEFSHFOWTE-UHFFFAOYSA-K tri(quinolin-8-yloxy)alumane Chemical compound [Al+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 TVIVIEFSHFOWTE-UHFFFAOYSA-K 0.000 claims description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 101710006547 Hsp70Ab Proteins 0.000 claims description 4
- 206010022114 Injury Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 3
- 206010059512 Apoptosis Diseases 0.000 claims description 3
- 208000006673 Asthma Diseases 0.000 claims description 3
- 210000004556 Brain Anatomy 0.000 claims description 3
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 3
- 208000001756 Virus Disease Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005336 allyloxy group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- KDPNMIGRDLVAQO-UHFFFAOYSA-N cyanomethyl hypochlorite Chemical compound ClOCC#N KDPNMIGRDLVAQO-UHFFFAOYSA-N 0.000 claims description 3
- 201000003883 cystic fibrosis Diseases 0.000 claims description 3
- 201000009273 endometriosis Diseases 0.000 claims description 3
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 201000011066 hemangioma Diseases 0.000 claims description 3
- 230000001506 immunosuppresive Effects 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 200000000018 inflammatory disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N Protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 101710027366 ACVRL1 Proteins 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 110
- 239000000243 solution Substances 0.000 description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 239000007787 solid Substances 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 125000004494 ethyl ester group Chemical group 0.000 description 35
- 239000000725 suspension Substances 0.000 description 35
- 230000014759 maintenance of location Effects 0.000 description 34
- 238000004166 bioassay Methods 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 24
- 210000004027 cells Anatomy 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- 229910052938 sodium sulfate Inorganic materials 0.000 description 23
- 235000011152 sodium sulphate Nutrition 0.000 description 23
- 239000002904 solvent Substances 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000008079 hexane Substances 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 102000005431 Molecular Chaperones Human genes 0.000 description 14
- 108010006519 Molecular Chaperones Proteins 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 12
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 150000003254 radicals Chemical group 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- AECPBJMOGBFQDN-YMYQVXQQSA-N Radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 9
- QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000259 anti-tumor Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 230000004059 degradation Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000002875 fluorescence polarization Methods 0.000 description 7
- 230000001105 regulatory Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- OZTNSQJDHIHJGH-UHFFFAOYSA-N 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound NC1=NC(Cl)=C2C=C(C(O)=O)SC2=N1 OZTNSQJDHIHJGH-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- CKTNHGVJKUQEBM-UHFFFAOYSA-N ethylazanide Chemical compound CC[NH-] CKTNHGVJKUQEBM-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 101700067048 CDC13 Proteins 0.000 description 4
- 229910014455 Ca-Cb Inorganic materials 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 102100017052 HSP90AA1 Human genes 0.000 description 4
- 101710033238 HSP90AA1 Proteins 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-Benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 102000034451 ATPases Human genes 0.000 description 3
- 108091006096 ATPases Proteins 0.000 description 3
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 101700025368 ERBB2 Proteins 0.000 description 3
- 102100016662 ERBB2 Human genes 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100009909 HSP90B1 Human genes 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102100011911 TRAP1 Human genes 0.000 description 3
- 108060008602 TRAP1 Proteins 0.000 description 3
- AYUNIORJHRXIBJ-TXHRRWQRSA-N Tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000001184 potassium carbonate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 229910052904 quartz Inorganic materials 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091006008 signal transducing proteins Proteins 0.000 description 3
- 102000034377 signal transducing proteins Human genes 0.000 description 3
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- YHUALAKPBMDCSC-UHFFFAOYSA-N 2,5-diamino-4-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C(N)=C(C(O)=O)SC2=NC(N)=NC=1C1=CC=CC=C1 YHUALAKPBMDCSC-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical compound NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- KZDGIGXMLMGLEI-UHFFFAOYSA-N 2-amino-4-(1H-indol-3-yl)thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C1=CC=C2C(C=3N=C(N=C4SC(=CC4=3)C(O)=O)N)=CNC2=C1 KZDGIGXMLMGLEI-UHFFFAOYSA-N 0.000 description 2
- NZBWAXCSTXFOGP-UHFFFAOYSA-N 2-amino-4-(2,4-dichloro-5-hydroxyphenyl)-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C1=CC(O)=C(Cl)C=C1Cl NZBWAXCSTXFOGP-UHFFFAOYSA-N 0.000 description 2
- YJBSPILVWVVBBY-UHFFFAOYSA-N 2-amino-4-(2,4-dichloro-5-hydroxyphenyl)-N-propan-2-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NC(C)C)=CC2=C1C1=CC(O)=C(Cl)C=C1Cl YJBSPILVWVVBBY-UHFFFAOYSA-N 0.000 description 2
- URAYNMTWWPXFMK-UHFFFAOYSA-N 2-amino-4-(2,4-dichloro-5-phenylmethoxyphenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C=C(C(O)=O)SC2=NC(N)=NC=1C(C(=CC=1Cl)Cl)=CC=1OCC1=CC=CC=C1 URAYNMTWWPXFMK-UHFFFAOYSA-N 0.000 description 2
- YBOQPYLNHMPHDP-UHFFFAOYSA-N 2-amino-4-chloro-6-(2,4-dimethylphenyl)pyrimidine-5-carbaldehyde Chemical compound CC1=CC(C)=CC=C1C1=NC(N)=NC(Cl)=C1C=O YBOQPYLNHMPHDP-UHFFFAOYSA-N 0.000 description 2
- FOSZENPYKBPMAO-UHFFFAOYSA-N 2-amino-4-oxo-6-phenyl-1H-pyrimidine-5-carbonitrile Chemical compound O=C1NC(N)=NC(C=2C=CC=CC=2)=C1C#N FOSZENPYKBPMAO-UHFFFAOYSA-N 0.000 description 2
- UKUGXVOBAXDZTG-UHFFFAOYSA-N 2-amino-4-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C=C(C(O)=O)SC2=NC(N)=NC=1C1=CC=CC=C1 UKUGXVOBAXDZTG-UHFFFAOYSA-N 0.000 description 2
- GVNBLVHAGMPGKY-UHFFFAOYSA-N 2-amino-5-methyl-4-phenylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C(C)=C(C(N)=O)SC2=NC(N)=NC=1C1=CC=CC=C1 GVNBLVHAGMPGKY-UHFFFAOYSA-N 0.000 description 2
- NGYUGCOXEIFIMD-UHFFFAOYSA-N 2-amino-6-phenyl-4-sulfanylidene-1H-pyrimidine-5-carbonitrile Chemical compound S=C1NC(N)=NC(C=2C=CC=CC=2)=C1C#N NGYUGCOXEIFIMD-UHFFFAOYSA-N 0.000 description 2
- SKDOBLDHRJVJSK-UHFFFAOYSA-N 2-amino-N-ethyl-4-phenylmethoxythieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1OCC1=CC=CC=C1 SKDOBLDHRJVJSK-UHFFFAOYSA-N 0.000 description 2
- LHJVNLIKNRRSMN-UHFFFAOYSA-N 2-amino-N-ethyl-4-phenylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C1=CC=CC=C1 LHJVNLIKNRRSMN-UHFFFAOYSA-N 0.000 description 2
- WTXXUAHMTVAQHW-UHFFFAOYSA-N 3-bromo-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1Br WTXXUAHMTVAQHW-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N Cathomycin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 229960002950 Novobiocin Drugs 0.000 description 2
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
- 101710027499 Os03g0268000 Proteins 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710006487 SSE2 Proteins 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N Sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 102100003095 TNFRSF1A Human genes 0.000 description 2
- 101710038526 TNFRSF1A Proteins 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- RVFHAHXRXAKVHO-UHFFFAOYSA-N ethyl 5-amino-4-benzoyl-3-methylthiophene-2-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(N)=C1C(=O)C1=CC=CC=C1 RVFHAHXRXAKVHO-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000005445 natural product Substances 0.000 description 2
- 229930014626 natural products Natural products 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic Effects 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960001663 sulfanilamide Drugs 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- HXXJMMLIEYAFOZ-UHFFFAOYSA-N (1-methylpiperidin-2-yl)methanol Chemical compound CN1CCCCC1CO HXXJMMLIEYAFOZ-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- TYONHSPZXLFWKI-UHFFFAOYSA-N (2,4-dimethylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(C)=C1 TYONHSPZXLFWKI-UHFFFAOYSA-N 0.000 description 1
- OSNSWKAZFASRNG-BMZZJELJSA-N (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-BMZZJELJSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- YJCPVMYUISTDKG-UHFFFAOYSA-N 1-phenylethenylboronic acid Chemical compound OB(O)C(=C)C1=CC=CC=C1 YJCPVMYUISTDKG-UHFFFAOYSA-N 0.000 description 1
- OFAPWTOOMSVMIU-UHFFFAOYSA-N 2,4-dichloro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=C(Cl)C=C1Cl OFAPWTOOMSVMIU-UHFFFAOYSA-N 0.000 description 1
- ZQPBOYASBNAXOZ-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetonitrile Chemical compound N#CCC1=CC=C2OCOC2=C1 ZQPBOYASBNAXOZ-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- LYTXQAFDYXTCPQ-UHFFFAOYSA-N 2-amino-4-(2,4-dichloro-5-phenylmethoxyphenyl)-N-propan-2-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NC(C)C)=CC2=C1C(C(=CC=1Cl)Cl)=CC=1OCC1=CC=CC=C1 LYTXQAFDYXTCPQ-UHFFFAOYSA-N 0.000 description 1
- ZZNQADDMVWWBFD-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-(2-hydroxyethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C1=CC(OCCO)=C(Cl)C=C1Cl ZZNQADDMVWWBFD-UHFFFAOYSA-N 0.000 description 1
- YXFLWIXTRZMDQT-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-[(1-methylpiperidin-2-yl)methoxy]phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C(C(=CC=1Cl)Cl)=CC=1OCC1CCCCN1C YXFLWIXTRZMDQT-UHFFFAOYSA-N 0.000 description 1
- KQRDVNUCOWRFLN-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C1=CC(OCCN(CC)CC)=C(Cl)C=C1Cl KQRDVNUCOWRFLN-UHFFFAOYSA-N 0.000 description 1
- IARCGYNTDFUEBB-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl]-N-propan-2-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C1=C(Cl)C(OCCN(CC)CC)=CC(C=2C=3C=C(SC=3N=C(N)N=2)C(=O)NC(C)C)=C1Cl IARCGYNTDFUEBB-UHFFFAOYSA-N 0.000 description 1
- ZSJKNQGKXJOZEK-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl]thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C1=C(Cl)C(OCCN(CC)CC)=CC(C=2C=3C=C(SC=3N=C(N)N=2)C(O)=O)=C1Cl ZSJKNQGKXJOZEK-UHFFFAOYSA-N 0.000 description 1
- WDSKPKKRTGBBIP-UHFFFAOYSA-N 2-amino-4-phenylmethoxythieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C=12C=C(C(O)=O)SC2=NC(N)=NC=1OCC1=CC=CC=C1 WDSKPKKRTGBBIP-UHFFFAOYSA-N 0.000 description 1
- OTTPFWBENUFHPX-UHFFFAOYSA-N 2-amino-4-phenylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)N)=CC2=C1C1=CC=CC=C1 OTTPFWBENUFHPX-UHFFFAOYSA-N 0.000 description 1
- QKUFXQOSRCUYKI-UHFFFAOYSA-N 2-amino-6-(2,4-dimethylphenyl)-4-sulfanylidene-1H-pyrimidine-5-carbaldehyde Chemical compound CC1=CC(C)=CC=C1C1=NC(N)=NC(S)=C1C=O QKUFXQOSRCUYKI-UHFFFAOYSA-N 0.000 description 1
- USHWRQQTMDOXSU-UHFFFAOYSA-N 2-amino-N-cyclopropyl-4-(2,4-dimethylphenyl)thieno[2,3-d]pyrimidine-6-sulfonamide Chemical compound CC1=CC(C)=CC=C1C1=NC(N)=NC2=C1C=C(S(=O)(=O)NC1CC1)S2 USHWRQQTMDOXSU-UHFFFAOYSA-N 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- HLMHCDKXKXBKQK-UHFFFAOYSA-N 2-bromoethyl(diethyl)azanium;bromide Chemical compound Br.CCN(CC)CCBr HLMHCDKXKXBKQK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- XNINAOUGJUYOQX-UHFFFAOYSA-M 2-cyanobutanoate Chemical compound CCC(C#N)C([O-])=O XNINAOUGJUYOQX-UHFFFAOYSA-M 0.000 description 1
- 125000000872 2-diethylaminoethoxy group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- XQQUMVFUJYJRSZ-UHFFFAOYSA-N 4-(2,4-dimethylphenyl)thieno[2,3-d]pyrimidin-2-amine Chemical compound CC1=CC(C)=CC=C1C1=NC(N)=NC2=C1C=CS2 XQQUMVFUJYJRSZ-UHFFFAOYSA-N 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N 4-Methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- LUIMXIDOSHHWCZ-UHFFFAOYSA-N 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde Chemical compound CC1=CC=C(C=O)C=C1B1OC(C)(C)C(C)(C)O1 LUIMXIDOSHHWCZ-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940040526 Anhydrous Sodium Acetate Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100017711 BLNK Human genes 0.000 description 1
- 101700001790 BLNK Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- SGTFFMMYXSNEHB-UHFFFAOYSA-M C(C)(=O)[O-].[K+].C(C)OC(=O)C1=CC2=C(N=C(N=C2C2=C(C=C(C(=C2)OCC2=CC=CC=C2)Cl)Cl)N)S1 Chemical compound C(C)(=O)[O-].[K+].C(C)OC(=O)C1=CC2=C(N=C(N=C2C2=C(C=C(C(=C2)OCC2=CC=CC=C2)Cl)Cl)N)S1 SGTFFMMYXSNEHB-UHFFFAOYSA-M 0.000 description 1
- 102100005550 C14orf180 Human genes 0.000 description 1
- 101710027095 C14orf180 Proteins 0.000 description 1
- 101700008359 CDK4 Proteins 0.000 description 1
- 102100019398 CDK4 Human genes 0.000 description 1
- JZXRVIDEKIQFCM-UHFFFAOYSA-N CO.C(C)[NH-] Chemical compound CO.C(C)[NH-] JZXRVIDEKIQFCM-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N Deuterated acetone Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100017445 HSPB1 Human genes 0.000 description 1
- 101700062887 HSPB1 Proteins 0.000 description 1
- 101700013735 HSPB3 Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N Herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N Iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- JTPUMZTWMWIVPA-UHFFFAOYSA-O Isopropamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 JTPUMZTWMWIVPA-UHFFFAOYSA-O 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102100011552 LCK Human genes 0.000 description 1
- 101700033896 LCK Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-Methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N N-Propyl bromide Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 101700050594 NR1K1 Proteins 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 241001417528 Nematistiidae Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N Phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003055 Prion Disease Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 101700007719 RAF1 Proteins 0.000 description 1
- 102100016115 RAF1 Human genes 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 229910020169 SiOa Inorganic materials 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N Sodium sulfide Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 101710026335 TP53 Proteins 0.000 description 1
- 102000004591 Telomerase Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- YKTZLHLBQGCFQX-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-3-yl]boronic acid Chemical compound C12=CC=CC=C2C(B(O)O)=CN1S(=O)(=O)C1=CC=CC=C1 YKTZLHLBQGCFQX-UHFFFAOYSA-N 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001120 cytoprotect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HDITUCONWLWUJR-UHFFFAOYSA-N diethylazanium;chloride Chemical compound [Cl-].CC[NH2+]CC HDITUCONWLWUJR-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 108060003523 dnaK Proteins 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- KOIROMZCNBIZGC-UHFFFAOYSA-N ethyl 2,5-diamino-4-phenylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C(N)=C(C(=O)OCC)SC2=NC(N)=NC=1C1=CC=CC=C1 KOIROMZCNBIZGC-UHFFFAOYSA-N 0.000 description 1
- MUUQXITYIXKKPT-UHFFFAOYSA-N ethyl 2-amino-4-(2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)-3H-thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound S1C(C(=O)OCC)=CC2=C1N=C(N)NC2=C1C=CC(=O)C=C1C MUUQXITYIXKKPT-UHFFFAOYSA-N 0.000 description 1
- RVSQDXBPGDMBIQ-UHFFFAOYSA-N ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C(N)N=C2SC(C(=O)OCC)=CC2=C1Cl RVSQDXBPGDMBIQ-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- DWRWSNAREGLUHZ-UHFFFAOYSA-N ethyl pyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=N1 DWRWSNAREGLUHZ-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000030647 heat shock protein 90 family Human genes 0.000 description 1
- 108091014034 heat shock protein 90 family Proteins 0.000 description 1
- 101710025516 hsp90a.1 Proteins 0.000 description 1
- 101700015965 hspD Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960001737 isopropamide Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer:wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)S-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk'and Alk 2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -(C=S)-, -S02-, -C(=O)O-, -C(=O) NR A- , -C(=S)NR A-, -S02NR A-, -NR AC(=O)_, -NR AS02- or-NR A-wherein R A is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical;and R4 is a carboxylic ester, carboxamide or sulfonamide group.
Description
COMPOUNDS OF PYRIMIDOTIOFENO
Field of the Invention This invention relates to substituted bicyclic [2,3-d] pyrimidine compounds (hereinafter referred to as "pyrimidothiophene") having HSP90 inhibitory activity, to the use of such compounds in medicine, in relation to diseases that have a response to inhibition of HSP90 activity such as cancers, and to pharmaceutical compositions containing such compounds. BACKGROUND OF THE INVENTION Molecular chaperons maintain the proper folding and conformation of proteins and are crucial in regulating the balance between protein synthesis and degradation. They have proved important in regulating many important cellular functions, such as cell proliferation and apoptosis (Jolly and Morimoto, 2000, et al., 1998, Smith, 2001). Heat Shock Proteins (HSP) Exposure of cells to various environmental stresses, including heat shock, alcohols, metals, heavy and oxidative stress, results in the cellular accumulation of various chaperones commonly known as heat shock proteins ( HSP). The HSP induction protects the cell against injury by
Ref. -.170291 initial tension, improves the recovery and leads to the maintenance of a stress-tolerant state. It has also become clear, however, that certain HSPs can also play an important molecular chaperon role under normal stress-free conditions by regulating the correct folding, degradation, localization and function of a growing list of important cellular proteins. There are several families of ultigenes of the HSP, with products of individual genes that vary in the expression, function and cellular location. They are classified according to molecular weight, for example, HSP70, HSP90 and HSP27. Various diseases in humans can be acquired as a result of poor protein folding (reviewed in Tytell et al., 2001, Smith et al., 1998). Thus, the development of therapies which fragment the machinery of molecular chaperones may prove beneficial. In some conditions
(for example Alzheimer's disease, prion diseases and Huntington's disease), misfolded proteins can cause protein aggregation that results in neurodegenerative disorders. Also, misfolded proteins can result in loss of function of the wild-type protein, which leads to dysregulated physiological and molecular functions in the cell. HSPs have also been implicated in cancer. For example, there is evidence of the differential expression of HSP which can be related to the stage of tumor progression (Martin et al., 2000, Conroy et al., 1996, Kawanishi et al., 1999, Jameel et al. , 1992; Hoang et al., 2000; Lebeau et al., 1991). As a result of the participation of HSP90 in various critical oncogenic trajectories, and the discovery that certain natural products with anti-cancer activity are targeting this molecular chaperone, the fascinating new concept has developed that by inhibiting the function of HSP it can be useful in the treatment of cancer. The first molecular chaperone inhibitor is currently undergoing clinical trials. HSP90 HSP90 constitutes about 1-2% of the total cellular protein, and is usually present in the cell as a dimer in association with one of several other proteins (see for example, Pratt 1997). It is essential for cell viability and shows dual chaperon functions (Young et al., 2001). It plays a key role in the response to cell stress by interacting with many proteins after their native conformation has been altered by various environmental stresses such as heat shock, ensuring adequate protein folding and avoiding non-specific aggregation (Smith et al. al., 1998). In addition, recent results suggest that HSP90 may also play a role in buffering against the effects of mutation, presumably by correcting the inadequate fold of mutant proteins (Rutherford and Lindquist, 1998). However, HSP90 also has an important regulatory role. Under normal physiological conditions, together with a homolog and GRP94 endoplasmic reticulum, HSP90 plays a maintenance role in the cell, maintaining the conformational stability and maturation of various key client proteins. These can be subdivided into three groups; (a) steroid hormone receptors, (b) Ser / Thr or tyrosine kinases (eg, ERBB2, RAF-1, CDK4, and LCK), and (c) a collection of apparently unrelated proteins, eg mutant p53 and the catalytic subunit of telomerase hTERT. All these proteins play key regulatory roles in many physiological and biochemical processes in the cell. The new HSP90 client proteins are continuously identified. The highly conserved family of HSP90 in humans consists of four genes, nominally the cytopolic HSP90a and HSP90β isoforms (Hickey et al., 1989), GRP94 in the endoplasmic reticulum (Aragón et al., 1999), and HSP75 / TRAP1 in the matrix of the itocondria (Felts et al., 2000). It is believed that all members of the family have a similar mode of action but are linked to different client proteins depending on their location within the cell. For example, ERBB2 is known to be a GRP94 specific client protein (Aragón et al., 1999) and the tumor necrosis factor receptor type 1 (TNFR1) and RB has been shown to be TRAP1 clients (Song et al. ., 1995; Chen et al., 1996). HSP90 participates in a series of complex interactions with a range of regulatory and client proteins (Smith, 2001). Although the precise molecular details remain to be obtained, crystallographic biochemical and X-ray studies (Prodromou et al., 1997; Stebbins et al., 1997) carried out over the last few years have provided increasingly detailed insights into the function of the chaperone of HSP90. After an early controversy on this issue, it is now clear that HSP90 is an ATP-dependent molecular chaperone (Prodromou et al, 1997), with the dimerization of the nucleotide binding domains that are essential for the hydrolysis of ATP, which In turn, it is essential for the function of the chaperone (Prodromou et al, 2000a). The ATP binding results in the formation of a toroidal dimer structure in which the N-terminal domains come into closest contact with one another, resulting in a conformational change known as the 'clamp mechanism' (Prodromou and Pearl, 2000b). Known HSP90 Inhibitors The first class of HSP90 inhibitors to be discovered was in the benzoquinone ansamycin class, which includes the compounds herbimycin A and geldanamycin. They were shown to invert the malignant phenotype of the fibroblasts transformed by the v-Src oncogene (Uehara et al., 1985), and subsequently showed potent antitumor activity both in in vitro models (Schulte et al., 1998) and in animal models in vivo (Supko et al., 1995). Affinity matrix and immunoprecipitation studies have shown that the important mechanism of action of geldanamycin involves binding to HSP90 (Whitesell et al., 1994, Schulte and Neckers, 1998). Additionally, X-ray crystallographic studies have shown that geldamamycin competes in the binding site
ATP and inhibits the intrinsic activity of HSP90 ATPase
(Prodromou et al., 1997; Panaretou et al., 1998). This in turn prevents the formation of mature multimeric HSP90 complexes able to form chaperones with the client proteins. As a result, the client proteins are targeted for degradation via the protease pathway of uchiquitin. 17-Allylamino, 17-derratoxygelandanamycin (17AAG) retains the property of HSP90 inhibition resulting in suppression of client protein and antitumor activity in cell cultures and in xenoingerto models (Schulte et al, 1998; Kelland et al. al, 1999), but has a significantly lower epatotoxicity than geldanamycin (Page et al, 1997). 17AAG is currently being evaluated in Phase I clinical trials.
Radicicol is a macrocyclic antibiotic that is shown to reverse the malignant phenotype of fibroblasts transformed by v-Src and v-Ha-Ras (Kwon et al, 1992; Zhao et al, 1995). It was shown to degrade various signaling proteins as a consequence of inhibition of HSP90 (Shulte et al., 1998). Crystallographic X-ray data confirmed that radicicol also binds to the N-terminal domain of HSP90 and inhibits the intrinsic activity of ARPase (Roe et al., 1998). Radicicol lacks antitumor activity in vivo due to the unstable chemical nature of the compound. It is known that coumarin antibiotics bind to the gyrase of bacterial DNA at an ATP binding site homologous to that of HSP90. Coumarin, novobiocin, was shown to bind to the carboxy terminus of HSP90, that is, at a site different from that occupied by the benzoquinone and radicicol ansamycins which binds at the N terminus (Marcu et al., 2000b). However, this still results in the inhibition of HSP90 function and the degradation of various signaling proteins that form chaperones with HSP90 (Marcu et al., 2000a). Geldanamycin can not bind subsequent HSP90 to novobiocin; this suggests that there must be some interaction between the N terminal and the C terminal domains, and is consistent with the view that both sites are important for the HSP90 chaperone properties.
An inhibitor of purine-based HSP90, PU3, has been shown to result in the degradation of signaling molecules, including ERBB2, and to arrest cell cycle arrest and differentiation in breast cancer cells (Chiosis et al., 2001). The patent publications WO 2004/050087 and WO2004 / 056782 refer to known classes of pyrazole derivatives which are inhibitors of HSP90. HSP90 As a Therapeutic Objective Because of its role in regulating various signaling pathways that are crucially important in driving the tumor phenotype, and the discovery that certain bioactive natural products exert their effects through HSP90 activity, the HSP90 molecular chaperone is is currently evaluating as a new target for the development of an anticancer drug (Neckers et al., 1999). The predominant mechanism of action of geldanamycin, 17AAG, and radicicol involves the binding of HSP90 to the ATP binding site located in the N-terminal domain of the protein which leads to the inhibition of the intrinsic ATPase activity of HSP90 ( see, for example, Prodromou et al., 1997; Stebbins et al., 1997; Panaretou et al., 1998). The inhibition of HSP90 ATPase activity prevents the recruitment of co-chaperones and encourages the formation of a type of HSP90 heterocomplex from which these client proteins are directed to degradation via the pathway of proteasone ubiquitin (see for example , Neckers et al., 1999; Kelland et al., 1999). Treatment with HSP90 inhibitors leads to the selective degradation of important proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes that are fundamentally important in cancer. The inhibition of HSP90 function has been shown to cause the selective degradation of important signaling proteins involved in cell proliferation, regulation of the cell cycle and apoptosis, processes that are fundamentally important and that are commonly deregulated in cancer (see for example, Hostein et al., 2001). An attractive reasoning to develop drugs against this objective for use in the clinical setting is that by simultaneously suppressing proteins associated with the transformed phenotype, a strong antitumor effect can be achieved and a therapeutic advantage against cancer versus normal cells can be achieved. These events in the downward direction of HSP90 inhibition are believed to be responsible for the antitumor activity of HSP90 inhibitors in cell culture and in animal models (see, eg, Schulte et al., 1998).; Kelland et al., 1999).
Brief Description of the Invention The present invention relates to the use of a class of substituted thieno [2,3-d] pyrimidine compounds
(hereinafter referred to as pyrimidotines) as HSP90 inhibitors, for example for the inhibition of the proliferation of cancer cells. A central pyrimidothiophene ring with aromatic substitution at an anil carbon atom are aspects of the principle characterization of the compounds to which the invention relates. Detailed Description of the Invention In a broad aspect, the present invention provides the use of a compound of Formula (I), or a salt, N-oxide, hydrate, or solvate thereof in the preparation of a composition for the inhibition of HSP90 activity in vitro or in vivo:
wherein R2 is a group of Formula (IA): - (Ar1) ™ - (Alq1) p- (Z) r- (Alq2) 3-Q (IA) wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C2-C3 alkenylene or C3-C3 alkylene radicals, m, p, r and s independently are 0 or 1, Z is -0-, -S-, - (C = 0) -, - ( C = S) -, -S02-, - (C = 0) 0-, -C (= 0) NRA-, -C (= S) NRA-, -S02NRA-, ~ NRAC (= 0) -, - NRAS02-, or -NRA-wherein R is hydrogen or C? -C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted alkyl (Cx-Cg), aryl or heteroaryl radical; Y
R 4 is a carboxylic ester, carboxamide or sulfonamide group. In another broad aspect, the invention provides a method of treating diseases that are responsive to inhibition of HSP90 activity in mammals, which method comprises administering to the mammal an amount of a compound as defined in claim 1 effective for inhibition of HSP90 activity. The in vivo use, and method, of the invention applies to the treatment of diseases in which HSP90 activity is involved, including use for immunosuppression or treatment of viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis. , type I diabetes, lupus, psoriasis and inflammatory bowel disease; disease related to cystic fibrosis angiogenesis such as diabetic retinopathy, hemangiomas and endometriosis; or for the protection of normal cells against the toxicity induced by chemotherapy; or diseases where the failure to experience apoptosis is a fundamental factor; or protection from hypoxia-ischemic injury due to the elevation of Hsp70 in the heart and brain; cenurosis / CJD, Huntingdon or Alzheimer's disease. The use for the treatment of cancer is especially indicated. Publications WO 01/62233, Transition Metal Chemistry Vol. 19, 1994, pages 335-339, Journal of Heterocyclic Chemistry Vol. 30, 1993, pages 1065-1072 and Synthesis No. 5, 1983, pages 402-404, describe compounds specific ones that fall within Formula (I) above, or relate to classes of compounds that encompass some compounds of Formula (I). However, most of the compounds of Formula (I) with which the foregoing broad aspects of the invention refer, are considered novel in their own right. The invention includes such novel compounds, and in particular compounds of the formula (I), and salts, N-oxides, hydrates or solvates thereof: wherein R2 is a group of the Formula (IA): - (Ar1) m - (Alk1) p- (Z) r- (Alk2) ß-Q (IA) wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 Y "Alk2 are optionally substituted divalent C2-C3 alkylene or C2-C3 alkenylene radicals , m, p, rys are independently 0 or 1, Z is -O-, -S-, - (C = 0) -, - (C = S) -, -S02-, C (= 0) 0-, -C (= 0) NRA-, -C (= S) NRA-, -S02NRA-, -NRAC (= 0) -, -NRAS02- or -NRA- wherein RA is hydrogen or C? -C6 alkyl, and Q is hydrogen or an optionally substituted heterocyclic or carbocyclic radical; R3 is hydrogen, an optional substituent, or an alkyl radical (C? -C6), aryl or heteroaryl; and R is a carboxylic ester, carboxamide or sulfonamide group, WITH THE CONDITION THAT (i) R3 is not -NH2 or (ii) when R4 is -C00CH3 and R3 is hydrogen then R2 is not ethylamino, diethylamino, phenylamino or -N (Ph) (C2H5) wherein Ph is phenyl. As used herein: the term "carboxyl group" refers to a group of the Formula -COOH; the term "carboxyl ester group" refers to a group of the formula -COOR, wherein R is a radical currently or by a notion derived from the hydroxyl compound ROH; and the term "carboxamide group" refers to a group of the Formula -C0NRaRb, wherein -NRaRb is an amino group (including cyclic amino) currently or by a notion derived from ammonia or the amine HNRaRb; the term "sulfonamido group" refers to a group of the Formula -S02NRaRb, wherein -NRaRb is an amino group (including cyclic amino) currently or by a notion derived from the ammonia or the amine HNRaRb. As used herein, the term "alkyl (Ca-Cb)" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl. As used herein the term "divalent alkylene radical (Ca-Cb)" wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valencies.
As used herein the term "alkenyl (Ca-Cb)" wherein a and b are integers refers to a straight or branched chain alkenyl portion having from a to b carbon atoms having at least one double bond of any E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1 and 2-butenyl and 2-methyl-2-propenyl. As used herein, the term "divalent alkenylene radical (Ca-Cb)" refers to a hydrocarbon chain having from a to b carbon atoms, at least one double bond and two unsatisfied valencies. As used herein, the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. As used herein, the term "cycloalkenyl" refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. As used herein, the term "aryl" refers to a mono, bi or tricyclic carbocyclic aromatic radical. Illustrative of such phenyl, biphenyl and naphthyl radicals are illustrative.
As used herein, the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic, cycloalkyl, and cycloalkenyl aryl radicals. As used herein, the term "heteroaryl" refers to a mono, bi or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such thienyl, benzthienyl, furyl, benzfurilo, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, piraziolilo, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, tiadazolilo, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, and indazolyl . As used herein, the non-qualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular refers to a non-aromatic mono, bi or tri-cyclic radical containing one or more heteroatoms selected from S, N and O, and for the groups consisting of a non-aromatic monocyclic radical containing one or more such heteroatoms which are covalently linked to another radical or a monocyclic carbocyclic radical. Illustrative of such radicals groups pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, tiadazolilo, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranilo, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl , ethylenedioxyphenyl, maleimido and succinimido. Unless otherwise specified in the context in which this occurs, the term "substituted" is applied to any amount herein that means substituted with at least one substituent, for example selected from alkyl (CL-CS) , alkoxy (C? -C6), hydroxy, hydroxyalkyl (C? -C6), mercapto, mercaptoalkyl (C? -C3), alkylthio (C? -C6), halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro , nitrile (-CN), oxo, phenyl, -COOH, -COORA, -C0RA, -S02RA, -CONH2, -S02NH2, -CONHRA, -S02NHRA, -CONRARB, -S02NRARB, -NH2, -NHRA, -NRARB, -OCONH2, -OCONHRA, -OCONR ?, RB, -NHC0RA, -NHCOORA, -NRBCOORA, -NHS020RA, -NRBS020RA, -NHC0NH2, -NRAC0NH2, -NHC0NHRB, -NRACONHRB, NHCONRARB, or -NRAC0NRARB wherein RA and RB are independently an alkyl group (C? -C6). An "optional substituent" can be one of the above substituent groups. As used herein, the term "salt" includes an addition base, an addition acid and quaternary salts, the compounds of the invention which are acids can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, for example sodium and potassium hydroxides; alkaline earth metal hydroxides eg calcium, barium and magnesium hydroxides; with organic bases for example N-ethyl piperidine, dibenzylamino and the like. Those compounds (I) which are basic to form salts, including pharmaceutically and veterinarily acceptable salts with inorganic acids, for example with hydrohalic acids such as hydrochloric or hydrobromic acids, sulfuric acid, nitric acid or phosphoric acid and the like, and with organic acids for example with acetic, tartaric, succinic, fumaric, maleic, salicylic, citric, methanesulfonic and p-toluenesulfonic acids and the like. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection and Use by Stahll and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term "hydrate" is used when the solvent is water. The compounds to which the invention refers that can exist in one or more stereoisomeric forms, due to the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry in each chiral center or as atropisomers with stereochemistry R or S in each chiral axis. The invention includes all of these enantiomers and diastereomers and mixtures thereof. The so-called "prodrugs" of the compounds of Formula (I) are also within the scope of the invention. Thus certain derivatives of the compounds of the Formula (I) which may have little or no pharmacological activity by themselves may, when administered in or on the body, be converted to compounds of the formula (I) having the desired activity, example, by hydrolytic cleavage. Such derivatives are referred to as "prodrugs". Additional information on the use of prodrugs can be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. Roche, American Pharmaceutical Association). The prodrugs according to the invention can, for example, be produced by replacing the appropriate functionalities present in the compounds of the formula (I) with certain portions known to those skilled in the art as "proportions" as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo during drug administration. Some examples of metabolites include (i) wherein the compound of the formula (I) contains a methyl group, a hydroxymethyl derivative thereof (-CH3-> -CH20H): (ii) wherein the compound of the formula (I) contains an alkoxy group, a hydroxy derivative thereof (-0R-> -OH): (iii) wherein the compound of the formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NRXR2-> - NHR1 or -NHR2); (iv) wherein the compound of the formula (I) contains a secondary amino group, a primary derivative thereof (-NHR1-> -NH2): (v) wherein the compound of the formula (I) contains a phenyl portion, a phenol derivative thereof (-Ph-> - PhOH); and (v) wherein the compound of the formula (I) contains an amide group, a carboxylic acid derivative thereof (-C0NH2-> COOH). The radical R2 As stated, R2 is a group of the formula (IA): - (Ar1) m- (Alq1) p- (Z) r- (Alq2) sQ (IA) where in any compatible combination Ar1 is a optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, rys are independently 0 or 1, Z is -0-, -S-, - (C = 0) -, - (C = S) -, -S02-, -C (= 0) 0-, -C (0 =) NRA-, -C (= S) NRA-, -S02NRA-, -NRAC ( = 0) -, -NRAS02- or -NRA- where RA is hydrogen or C? -C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical. When it occurs in the radical R2, Ar1 can be, for example, a phenyl, cyclohexyl, pyridyl, morpholino, piperidinyl or piperazinyl ring. It is currently preferred that Ar1, when present, for a phenyl ring; Alk1 and Alk2 can be, for example, optionally substituted divalent radicals selected from -CH2, CH2CH2- or -CH = CH-. Optional substituents on Alk1 and Alq2 include, for example, mono or di (Cx-C3 alkyl) amino and C1-C3 alkoxy; and Z may be, for example, -0- or -NH; and Q is hydrogen. In a simple subclass of the compounds to which the invention relates, m is 1 and each of p, r and s is 0, and Q is hydrogen, so that R2 is aryl or optionally substituted heteroaryl. In such cases, R 2 may be, for example, phenyl, 2 or 3-thienyl, 2 or 3-furanyl, 2, 3 or 4-pyridinyl, morpholinyl or optionally substituted piperidinyl. Presently preferred are compounds wherein R2 is optionally substituted phenyl, for example where the optional substituents are selected from methyl, ethyl, n- or isopropyl, vinyl, allyl, methoxy, ethoxy, n-propyloxy, benzyloxy, allyloxy, cyanomethoxy chlorine, bromine, cyano, formyl, methyl, ethyl, or n-propyl-carbonyloxy, methyl or ethylaminocarbonyl. The groups of substituents more complexed which may occur in the ring R 2 include those (i) of the formula -0 (CH 2) I 1 Z 1 wherein n is 1, 2 or 3 and Z 1 is a primary, secondary, tertiary or cyclic, or an alkoxyC? -C6 group; or (ii) of the formula - (Alq3) mZ1 wherein Alq3 is a straight or branched chain divalent (C-C3) alkylene, m is 0 or 1, and Z1 is a primary, secondary, tertiary or cyclic amino group, or an alkoxyC? -C6 group. The preferred substitution positions in the phenyl ring are positions 2, 4 and 5. In other simple structures, m is 1, p, r and s are each again 0, and Q may be an optionally substituted carbocyclic or heterocyclic ring, for example a phenyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazinyl ring. In such cases Q is a direct substituent on the optionally substituted Ar1 ring. In more complex structures with which the invention relates, one or more of m, p, r and s can be 1 and Q can be hydrogen or an optionally substituted carbocyclic or heterocyclic ring. For example, p and / or s can be 1 and r can be 0, so Q is linked to Ar1 by an alkylene or alkenylene radical, for example a C? -C3 alkylene radical, which is optionally substituted. In other cases each of p, r and s can be 1, in which case, Q is linked to Ar 1 by an alkylene or alkenylene radical which is interrupted by the radical Z containing heteroatom. In still other cases, p and s can be 0 and r can be 1, in which case Q is linked to Ar1 by means of the radical Z containing heteroatom. Specific examples of the R2 groups used in the compounds of the invention include those present in the compounds of the Examples herein. The optional R3 substituent R3 is hydrogen or an optional substituent, as defined above. It is currently preferred that R3 is hydrogen. The group R4 When R4 is a carboxamide or sulfonamide group, examples include those of the formula -C0NRB (Alq) QRA -S02NRB (Alq) nRA wherein Alq is a divalent alkylene, alkenylene or alkynylene radical, for example a -CH2 radical -, -CH2-CH2-, -CH2-CH2-CH2-, -CH2CH = CH-, or -CH2CCCH2-, and the radical Alq can be optionally substituted, n is 0 or 1, RB is hydrogen or an alkyl group C -C5 or C2-C6 alkenyl, for example methyl, ethyl, n- or iso-propyl, or allyl. It is currently preferred that RB is hydrogen. RA is an optional substituent such as hydroxyl, amino (including mono- and di-alkylamino (Cx-C3)), carbamoyl (-C (= 0) NH2), -S020H, trifluoromethyl; or optionally substituted carbocyclic, for example cyclopropyl, cyclopentyl, cyclohexyl, phenyl optionally substituted by hydroxyl, amino, fluoro, chloro, bromo, 3,4 methylenedioxy, sulfamoyl (-S02NH2), -S020H, methoxy, methylsulfonyl, trifluoromethyl; or heterocyclyl, for example pyridyl, furyl, thienyl, diazolyl, N-piperazinyl, pyrrolyl, tetrahydrofuranyl, thiazolyl, 1-aza-bicyclo [2, 2, 2] octanyl, or N-morpholinyl, any of the heterocyclic rings can be substituted, example in a nitrogen ring by (C? -C3) alkyl, or RA and RB when taken together with the nitrogen to which they are bonded form an N-heterocyclic ring which may optionally contain one or more additional heteroatoms selected from O, S and N, and which can optionally be substituted on one or more C or N atoms in the ring, examples of such N-heterocyclic rings include morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl. It is currently preferred that R 4 is a carboxamide group. When R4 is a carboxylic ester group, examples include those of the Formula -C00RC wherein Rc is a C? -C6 alkyl group or a C2-C6 alkenyl, for example methyl, ethyl, n- or iso-propyl, or allyl; or an optionally substituted aryl or heteroaryl group, for example phenyl, pyridyl or optionally substituted thiazolyl; or an optionally substituted aryl (C 1 -C 6 alkyl) or heteroaryl (C 1 -C 3 alkyl) group such as benzyl or pyridylmethyl; or an optionally substituted cycloalkyl group such as cyclopentyl or cyclohexyl. Specific examples of the R groups used in the compounds of the invention include those presented in the compounds of the examples herein. A preferred subclass of the compounds to which the invention relates have the formula (II)
wherein A is a secondary amino group R10 is H, Cl, Br or CH3; R x is hydrogen, Cl, Br, CN, methyl, ethyl, n or isopropyl, vinyl or allyl; R12 is (i) a radical of the formula -0 (CH2) I1Z1 wherein n is 1, 2 or 3 and Z1 is a primary, secondary, tertiary or cyclic amino group, or a C6-C6 alkoxy group; or (ii) a radical of the formula - (Alq3) mZ1 wherein Alq3 is a straight or branched chain divalent (C-1-C3) alkylene, m is 0 or 1 and Z1 is a primary, secondary amino group, tertiary or cyclic, or an alkoxyC? -C6 group. In this subclass of the compounds (II) it is preferred that A is a secondary alkylaminoC-C6 group, for example wherein the C?-C3 alkyl substituent is selected from methyl, ethyl and n- and iso-propyl, and R12 is ( i) a radical of the formula -0 (CH2) IlZ1 wherein n is 1, 2 or 3 and Z1 is di (Cx-C3 alkyl) amino or C? -C3 alkoxy, for example wherein the alkyl C? -C3 are selected from methyl, ethyl and n- and iso-propyl. Specific compounds to which the invention refers include those of the examples, particularly those exemplified compounds having structure (II) above. There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention concerns, but everything depends on the known chemistry, which is known to the technician of synthetic organic chemistry. Thus, the compounds according to Formula (I) can be synthesized according to procedures described in the standard literature and are well known to those skilled in the art. Typical literature sources are "Advanced Organic Chemistry", 4th Edition (Wiley), J March, "Comprehensive Organic Transformation", 2nd Edition (Wiley), R.C. Larock, "Handbook of Heterocyclic Chemistry", 2nd Edition (Pergamon), A.R. Katritzky), journal articles such as those found in "Synthesis", "Acc. Chem. Res.", "Chem. Rev", or Primary literature sources identified by the Sources of standard literature online or from secondary sources such as "Chemical Abstracts" or "Beilstein". Such literature methods include those of the Preparative Examples herein, and methods analogous thereto. For example, the following general reaction scheme can be used:
The starting material is either commercially available or can be made according to the methods of the literature. Subsequent reactions can be carried out in R2, R3 or R4 to prepare additional compounds of Formula (I). The compounds of the invention are inhibitors of HSP90 and are useful in the treatment of diseases which respond to the inhibition of HSP90 activity such as cancers; viral diseases such as Hepatitis C (HCV) (Waxman, 2002); immunosuppression as in transplant (Bijlmakers, 2000 and Yorgin, 2000); anti-inflammatory diseases (Bucci, 2000) such as rheumatoid arthritis, asthma, MS, type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis (Fuller, 2000); diseases related to angiogenesis (Hur, 2002 and Kurebayashi, 2001); Diabetic retinopathy, hemangiomas, psoriasis, endometriosis and tumor angiogenesis. Also an Hsp90 inhibitor of the invention can protect normal cells against the toxicity induced by chemotherapy and is useful in diseases where the failure to undergo apoptosis is a fundamental factor. Such Hsp90 inhibitor may also be useful in diseases where the induction of a heat shock protein response or cell stress could be beneficial, for example, protection from a hypoxia-ischemic injury due to the elevation of Hsp70 in the heart (Hutter , 1996 and Trost, 1998) and brain (Plumier, 1997 and Rajder, 2000). An increase induced by the Hsp90 inhibitor in Hsp70 levels could also be useful in diseases where the protein does not attach or aggregation is a major cause, for example, neurogenerative disorders such as Cenurosis / CJD, Huntingdon and Alzheimer (Sittler, 2001; Trazelt, 1995 and Winklhofer, 2001). "In this manner, the invention also includes: (i) A pharmaceutical or veterinary composition comprising a compound of formula (I) above, together with a pharmaceutically or veterinarily acceptable carrier. The use of a compound of formula (I) above in the preparation of a composition for the composition for the inhibition of HSP90 activity in vitro or in vivo. (Iii) A method of treating diseases or conditions that respond to inhibition of the activity
HSP90 in mammals, which method comprises administering to the mammal an amount of a compound of formula (I) above effective to -inhibit the activity of HSP90. It will be understood that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed, age, body weight, general health, sex, diet, time of administration, route of administration, rate of administration. excretion, combination of the drug and the mechanism of cause and severity of the particular disease that undergoes therapy. In general, a suitable dose for formulations that are administered orally will usually be in the range of 0.1 to 3000 mg, once, twice or three times a day, or the equivalent daily amount administered by infusion or other routes. However, optimal dose levels and frequency of dosing will be determined by clinical trials as conventional in the art. The compounds to which the invention relates can be prepared for administration by any route consistent with their pharmacokinetic properties. Orally administrable compositions may be in tablets, capsules, powders, granules, dragees, liquid preparations or gels, such as oral, topical or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in a unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; filled for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; lubricants for the formation of tablets, for example, magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets can be coated according to a method well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, hydrogenated edible fats of gelatin, emulsifying agents for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerin, propylene glycol or ethyl alcohol, preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and conventional flavoring or coloring agents are desired. For topical application to the skin, the drug can be made in cream, lotion or ointment. The cream or ointment formulations that can be used for the drug are conventional formulations well known in the art, for example as described in standard pharmacy textbooks such as British Pharmacopoeia. The active ingredient can also be administered parenterally in a sterile medium. Depending on the vehicle and the concentration used, the drug can be suspended or dissolved in the vehicle. Advantageously, adjuvants such as anesthetic agents, preservatives and buffers in the vehicle can be dissolved in the vehicle. The following examples illustrate the preparation and activities of the specific compounds of the invention. Example 1 Ethyl ester of 2-amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid
Stage 1 Ethyl ester of 2-amino-4-chloro-tieno [2,3-d] pyrimidine-6-carboxylic acid
To a stirred mixture of 2-amino-4,6-dichloro-5-formyl-pyrimidine (1 eq.) And potassium carbonate (1 eq.) In acetonitrile at room temperature was added ethyl-2-mercaptoacetate (0.95 eq.). .) and the mixture was stirred at room temperature for three hours, followed by heating at 80 ° C for one hour. After cooling, the mixture was concentrated to dry in vacuo. Column chromatography on silica, eluting with ethyl acetate and hexanes, gives example 1 as a yellow powder. LC-MS retention time: 2 .371 minutes, [M + H] + 258. 0
Stage 2 (Suzuki reaction): Ethyl ester of 2-amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid
A solution of Example 1 step 1 (1 eq.), Phenyl boronic acid
(1.2 eq) and sodium carbonate (1.2 eq) in 1,4-dioxane and water (3.5: 1) were degassed by bubbling through nitrogen gas for 5 mins. The Pd (PPh3) 4 (0.05 eq.) Was added and the mixture is heated in a Personal Chemistry microwave synthesizer at 150 ° C for 10 minutes. After cooling and concentration in vacuo, preparative HPLC gives Example 2 as a white powder. LC-MS retention time: 2545 minutes, [M + H] + 300.10 This compound has 'A' activity in the fluorescence polarization assay described below. Example 2; Ethyl ester of 2-amino-4- (4-trif luoromethyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
prepared as per Example 1. LC-MS retention time: 2768 minutes, [M + H] + 368.1
XH NMR (400MHz, d6-DMSO): d = 1.07 (3H, t, J = 7.1 Hz), 4.09 (2H, q, J = 7.1 Hz), 7.25 (2H, br s), 7.68 (1 H, s ), 7.76 (2H, d, J = 8.0Hz), 7.85 (2H, d, J = 8. OHz). This compound has activity? B 'in the fluorescent polarization assay described below. The following compounds in Table 1 were synthesized and tested in the fluorescent polarization assay described below. Suzuki reactions were carried out as in the
Example 1 Step 2. The reductive amination reactions were carried out as per Example 33, as follows: Ethyl ester of 2-amino-4- (4-piperidin-1-methylmethyl-phenyl) -thieno [2, 3-d] pyridine-6-carboxylic acid (Example 33 in Table 1)
Pyrrolidine (5 equiv) was added to a suspension of ethyl ester of 2-amino-4- (4-formyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid (1 equiv) in methanol The reaction mixture was heated to reflux for 3.5 hours then cooled to room temperature. Sodium borohydride (3 equiv) was added and stirred for 10 mins. The mixture was concentrated in vacuo then partitioned between ethyl acetate and water. The phases were separated and the organic layer was washed with brine, dried and evaporated to a yellow solid. The crude product was purified by preparative HPLC. LC-MS retention time: 1,803 minutes, [M + H] + 383.
The chloride shift reactions were carried out as per Example 22 as follows: Methyl ester of 2-amino-4-benzylamino-thieno [2,3-d] pyrimidine-6-carboxylic acid (Example 22 in the Table 1)
The methyl ester of 2-amino-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid (10 Omg,
0. 39mmol), benzylamine (100μl) in 4mL of THF are exposed to MW irradiation at 110 ° C for 35 mins. The reaction was cooled to room temperature and worked (acid) and purified using standard conditions for a neutral compound. LC-MS: RT = 2.391 mins; MS m / z = 329 (M + 1). Note: The intensity and reaction time depends on the reactivity of the amine. For example, for less reactive amines (such as N-methyl aniline), suitable reaction conditions are MW 160 ° C for 30 mins and 0.5mL amine. The fourth column of Table 1 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 1
the
he
Example 42; 2-Amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid amide
The compound of Example 1 was suspended in concentrated ammonium hydroxide and heated on a Personal Chemistry microwave synthesizer at 140 ° C for 20 minutes. Concentration in vacuo gives example 42 as a white solid. LC-MS retention time: 1824 minutes, [M + H] + 271.10.
Example 43 2-Amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
Step 1: 2-Amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid
Sodium hydroxide (0.66 g, 16.5 mmol) was added to a suspension of 2-amino-phenyl-thieno [2,3-d] irimidine-6-carboxylic acid ethyl ester (Example 1) (1.00 g). 3.34 mmol) in ethanol (20 ml) and water
(2 ml). The mixture was refluxed for 1 hour
(providing a homogeneous pale yellow solution) and allowed to cool to room temperature.
The solvents were removed in vacuo and the solid residue was dissolved in water (30 mL) and cooled with an ice-water bath. The mixture was stirred and adjusted to pH 1-2 by the dropwise addition of concentrated hydrochloric acid. The resulting precipitate was filtered, washed with water, then ethanol and finally diethyl ether. The opaque white product was dried in vacuo to give 2-amino-4-phenyl-t-ene [2,3-d] pyrimidine-6-carboxylic acid as a colorless solid (0.784 g, 87%). LC / MS RT = 1845 min; m / z = 272 (M + H) + Step 2 2-Amino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
0- (7-Azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (0.380 g, 1.0 mmol) was added to 2-amino-4-phenyl-thieno acid [2, 3-d] pyrimidine-6-carboxylic acid (0.187 g, 0.69 mmol). This mixture was suspended in dimethylformamide (DMF)
(5.0 mL) and diisopropylethylamine (0.696 mL, 4.0 mmol) was added to provide a yellow solution. Diethylamine hydrochloride (0.122 g, 5.0 mmol) was added and the reaction mixture was heated for ten minutes at 100 ° C in a sealed vial on a microwave synthesizer. The DMF was removed in vacuo and the residue was partitioned between ethyl acetate (30 ml) and water (30 ml). The phases were separated and the organic phase was washed with saturated sodium chloride solution and dried over sodium sulfate. The mixture was filtered and the filtered solvents were removed in vacuo to leave a yellow solid which was adsorbed on silica gel and purified by flash chromatography on silica gel (20 g), eluting with a solvent gradient of 15 to 50%. ethyl acetate in hexane. This gives the ethylamide of 2-amino-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid as a pale yellow solid (0.051 g, 25%).
LCMS RT = 2.08 min; m / z = 299 (M + H) + 1 H NMR (400MHz, d 6 DMSO) 6 1.11 (t, 3H), 3.26 (m, 2H), 7.12 (s, 2H), 7.61 (m, 3H), 7.86 ( m, 2H), 8.03 (s, 1 H), 8.71 (t, 1 H). The compound of Example 43 has activity? A 'in the fluorescent polarization assay described below. The following compounds (Table 2) are made by the method of Example 43 from the corresponding ester (Table 1) and the appropriate amine. The final column of Table 2 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 2
Example 74
Ethyl ester of 2,5-diamino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl ester
Stage 1 2-amino-6-oxo-4-phenyl-1,6-dihydro-pyrimidine-5-carbonitrile
Benzaldehyde (15g, 141.3mmol, leq), guanidine carbonate (25.47g, 141.3mmol, leq), ethyl cyanoacetate (15.99g, 141. 3mmol, leq) and anhydrous sodium acetate (11.59g, 141.3mmol, leq) ) were added to 300ml of anhydrous pyridine and refluxed for 4 hours. The reaction was then cooled to room temperature and the solvent was removed under reduced pressure. The brown residue was triturated with 400 ml of aqueous acetic acid (30%) and filtered thoroughly. The yellow solid was then triturated with 300 ml of diethyl ether and filtered thoroughly to give 2-amino-6-oxo-4-phenyl-1,6-dihydro-pyrimidine-5-carbonitrile as an opaque white solid. Yield: 14.46g (48%) LCMS retention time = 1.34min, m / z calculated for C ??H9N40 213.22 (M + H), found 213.1
Step 2 2 -Amino-4-phenyl-6-thioxo-1,6-dihydro-pyrimidine-5-sarbonitrile
2-Amino-6-oxo-4-phenyl-1, 6-dihydro-pyrimidine-5-carbonitrile (0.200g, 0.942mol, leq) and phosphorus pentasulfide
(0.838g, 3.770mol, 4eq) were dissolved in 5ml of pyridine. The reaction was heated under reflux for 2 hours, cooled to room temperature and drained in 100 ml of water. The mixture was boiled for 1 hour, cooled to room temperature and extracted with dichloromethane. The combined organic extracts were washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was removed in vacuo and the orange residue was triturated with diethyl ether to give 2-amino-4-phenyl-6-thioxo-1,6-dihydro-pyrimidine-5-carbonitrile as a yellow solid. Yield: O.lldg (55%) CLEM retention time = 1.94min, m / z calculated for C11H9 4S 229.29 (M + H), found 229.1
Step 3 Ethyl ester of 2,5-diamino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid ester
Sodium (O.OlOg, 0.438 mmol, leq) was dissolved in 4 ml of anhydrous ethanol under nitrogen. 2-Amino-4-phenyl-6-thioxo-1,6-dihydro-pyrimidine-5-carbonitrile (O.lOOg, 0.438 mmol, leq) was added and the reaction was stirred at room temperature for 1 hour. The 2-bromoethylacetate (0.073 g, 0.438 mmol, 1 eq) was added. The reaction was stirred for an additional 30 minutes at room temperature. Then the sodium (O.OlOg, 0.438mmol, leq) dissolved in lml of anhydrous ethanol was added. The reaction was then refluxed for 5 hours. The reaction was cooled to room temperature and quenched with water. The precipitate was completely filtered and triturated with diethyl ether to give the ethyl ester of 2,5-diamino-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid as a yellow solid. Yield: 0.059g (43%) LCMS retention time = 2.42min, m / z calculated for C? 5H? 5N402S 315.38 (M + H), found 315.1 aH NMR (DMSO-d6, 2.50) d 1.19 (t, 3H , J = 7.1) # 4.13 (q, 2H, J = 7.1), 5.79 (bs, 2H), 7.29 (bs, 2H), 7.50-7.56 (m, 5H) This compound has activity B in the polarization test of fluorescence described below.
EXAMPLE 75 2-Amino-5-methyl-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid amide
Step 1: 5-Amino-4-benzoyl-3-methyl-thiophene-2-carboxylic acid ethyl ester
Prepared by the literature method Bryan P. McKibben, Craig H. Cart right, Arlindo L. Castelhano Tetrahedron Lett. 1999, 44, 5471 Step 2 2-Amino-5-methyl-4-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid amide
The guanidine carbonate was added to a solution of the 5-amino-4-benzoyl-3-methylthiophene-2-carboxylic acid ethyl ester, and the suspension was heated, 175 ° C, for ~ 3hrs., Under an atmosphere of nitrogen. The suspension was allowed to cool and the water was added. The mixture was extracted with ethyl acetate, the extracts were washed and dried. The solution was concentrated and the residue was purified by chromatography eluting with mixtures of ethyl acetate and hexane. CL holding time 2.17 minutes [M + H] + 285.1 (Run time 3.75mins). This compound has activity B in the fluorescent polarization assay described below. Additional examples prepared by methods similar to those described above are listed in Table 3. The fourth column of Table 3 establishes the activity of the compound in the fluorescence polarization assay described ab j o.
Table 3
Example 184 Ethyl ester of 2-amino-4- (4-hydroxy-2-methyl-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid
Step 1 Ethyl ester of 2-amino-4- (4-benzyloxy-2-methyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
2-Methyl-4-benzyloxyphenylboronic acid (225 mg, 0.93 mmol) was added to the ethyl ester of 2-amino-4-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid (Example 1; Stage 1) (200 mg, 0.776 mmol) in DMF (10 mL). NaHCO3 (1.0M aqueous solution, 2.33 mL) was added and the mixture was degassed with N2. The Pd (PPh3) 2Cl2 was added and the reaction mixture was heated to 80 degrees C for 5 hours. The reaction mixture was allowed to cool to room temperature and the DMF was removed in vacuo. The residue was partitioned between ethyl acetate (50 mL) and saturated NaCl (aq) (50 mL). The organic phase was dried over Na2SO4 and filtered, the filtered solvents were removed in vacuo to give a yellow oil which was purified by ion exchange chromatography (IST SCX-2 column) to give the product as a brown yellow solid ( 230 mg, 71%). CL-EM retention time: 2.852 minutes, [M + H] + 420 (Run time 3.75mins)
Step 2: 2-Amino-4- (4-hydroxy-2-methyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl ester
To a solution cooled in an ice bath of the ethyl ester of 2-amino-4- (4-benzyloxy-2-methyl-phenyl-thieno [2,3-d] pyrimidine-6-carboxylic acid (211 mg; 0.5 mmol) in dichloromethane (8 mL), BC13 (solution 1. OM in DCM, 1.51 mL, 1.5 mmol) was added. The reaction mixture was stirred for 30 mins and then aqueous ammonia was added (20 mL) and the reaction mixture was extracted with ethyl acetate (2 x 30 mL). The organic phase was dried over Na2SO4 and filtered, the filtered solvents were removed in vacuo to give a yellow solid which was purified by flash chromatography on silica gel (10g IST Flash, eluting 10 to 40% ethyl acetate in hexane) to provide the product as a colorless solid (102 mg, 62%). LC-MS retention time: 2,852 minutes, [M + H] + 420 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below.
Example 185 Ethyl ester of 2-amino-4- (2-methyl-4-propoxy-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
1-Bromopropane (15 uL, 0.17 mmol) was added to a solution of the ethyl ester of 2-amino-4- (4-hydroxy-2-methyl-phenyl) -thieno [2,3-d] pyrimidine. -6-carboxylic acid (50 mg: 0.152 mmol) and potassium carbonate (25 mg, 0.18 mmol) in DMF (15 mL). The reaction mixture was heated to 50 degrees C for 18 hours. The reaction mixture was allowed to cool and the solvent was removed in vacuo. The residue was partitioned between saturated aqueous sodium bicarbonate solution (10 mL) and ethyl acetate (20 mL). The organic phase was dried over NaSO and filtered, the filtered solvents were removed in vacuo to give a yellow solid which was purified by flash chromatography on silica gel (eluting with ethyl acetate in hexane) to give the product as a yellow solid. (45mg, 80%). CL-EM retention time: 2821 minutes, [M + H] + 372 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below. The following compounds (Table 4) are made by the method of Example 185, substituting the appropriate alkylating agent for bromopropane. The fourth column of Table 4 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 4
Example 196
Ethyl ester of 2-amino-4- (5-formyl-2-methyl-phenyl) thieno [2,3-d] pyrimidine-6-carboxylic acid Stage 1 3 -Bromo-4-methyl-benzaldehyde
Prepared as described by Eizenber and Ammons, Org
Prep and Reactions Int., 6 (5), 251-253 (1974) from p-tolualdehyde (12.0Og) Yield: 10.97 g (55%) LCMS retention time = 2.57min; without ionization. XR NMR (400 MHz; CDCl3) d 2.50 (s, 3H), 7.43 (d, 1H, J =
7. 8Hz), 7.75 (dd, 1H, J = 7.8 and 1.6 Hz), 8. 05 (d, 1 H, J =
1. 6 Hz), 9.94 (s, 1 H). Step 2 4-Methyl-3- (4, 4, 5, 5-tetramethyl- [1,3,2] dioxaborolan-2-yl) -benzaldehyde
To the mixture of 3-bromo-4-methyl-benzaldehyde (3.105 g;
. 6 mmol), bis (pinacolato) diboro (4.29 g, 16.86 mmol) and potassium acetate (4.59 g, 46.8 mmol) in dimethylformamide (60 mL) was degassed by nitrogen-evacuation purge (3 cycles), followed by bubbling nitrogen gas through the stirred reaction mixture for 5 minutes. The palladium acetate (0.120 g, 0.536 mmol) was added and the reaction mixture was heated to 85 degrees C (oil bath temperature) for 2.5 hours. The reaction mixture was allowed to cool to room temperature and the DMF was removed in vacuo. The residue was partitioned between ethyl acetate (150 mL) and water (150 mL) and the mixture was filtered through a pad of celite to remove the black Pd solids. The filter cake was washed with ethyl acetate (2 x 50 mL) and the combined filtrates were separated and the organic phase was washed with water (2 x 150 mL) then saturated sodium chloride solution (150 mL). Organic phase was dried over Na2SO4 and filtered, the filtered solvents were removed in vacuo to give a yellow oil which was purified by flash chromatography on silica gel (50g IST Flash, eluting with 0 to 10% ethyl acetate in hexane). ) to provide the product as a colorless solid Yield: 4.58 g, 85% LC-MS retention time = 2799 min; [M + H] + 247 XH NMR (400 MHz, CDC13) d 1.36 (s, 12H), 2.62 (s, 3H), 7.31 (d, 1H, J = 7.88 Hz), 7. 83 (dd, 1H, J = 7.88 and 1.9 Hz), 8.25 (d, 1H, J = 1.9 Hz), 9.98 (s) , 1 HOUR) .
Step 3 Ethyl ester of 2-amino-4- (5-formyl-2-methyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
The ethyl ester of 2-amino-4-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid (7.62 g, 29.57 mmol) was added to 4-methyl-3- (4.4, 5). , 5-tetramethyl- [1, 3, 2] dioxaborolan-2-yl) -benzaldehyde (7.28 g, 29.57 mmol) followed by sodium hydrogen carbonate (7.45 g, 88.71 mmol). DMF (110 mL) was added followed by water (22 mL) and the suspension was degassed by nitrogen-evacuation purge (3 cycles), followed by bubbling of nitrogen gas through the stirred reaction mixture for 5 minutes. The bis (triphenylphosphine) palladium (II) chloride (500 mg, 0.739 mmol) was added and the reaction mixture was heated to 85 degrees C (oil bath temperature) for 18 hours. The reaction mixture was allowed to cool to room temperature and the DMF was removed in vacuo. The residue was partitioned between ethyl acetate (500 mL) and water (400 mL) and the mixture was stirred vigorously for 15 min before filtering through a pad of celite to remove the Pd solids. The filter cake was washed with ethyl acetate (2 x 50 mL) and the combined filtrates were separated and the organic phase was washed with water (1 x 300 mL) then a saturated sodium chloride solution (250 mL). The organic phase was dried over Na 2 SO and filtered, and the filtered solvents were removed in vacuo to give a brown oily solid which was triturated with ethyl acetate to give the product as a brown solid (5.42 g, 56%). CL-EM retention time = 2.436 min; [M + H] + 342. X H NMR (400 MHz, d 6 -DMSO) 1.30 (t, 3 H), 2.38 (s, 3 H), 4.32 (q, 2 H), 7.48 (s, 2 H), 7.71 (d, 2H), 7.91 (s, 1H), 7.97 (d, 1H), 10.11 (s, 1H). This compound has activity A in the fluorescent polarization assay described below.
Example 197 2-Amino-4- (2-methyl-5-propylaminomethyl-phenyl) -thieno [2,3-d] irimidine-6-carboxylic acid ethylamide
Methanol (5mL) was added to the ethyl ester of 2-amino-4- (5-formyl-2-methyl-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid ester (100 mg, 0.29). mmol) and propylamine (0.586 mmol) was then added to the resulting suspension. The reaction mixture was heated to reflux (providing a homogenous brown solution) for 4 hours then allowed to cool to room temperature. Sodium borohydride (23 mg, 0. 58 mmol) was added and the reaction mixture was stirred for 30 mins. The methanol was removed in vacuo and the residue was partitioned between water (20 mL) and ethyl acetate.
(20 mL). The phases were separated and the organic phase was dried over Na 2 SO and filtered, and the filtered solvents were removed in vacuo to give a brown solid which was suspended in ethylamine 2.0M in methanol solution.
(5.0 mL, 10 mmol) and heated in a sealed tube at 85 degrees C overnight. The reaction mixture was allowed to cool and the solvents were removed in vacuo to give a brown solid which was triturated in hot ethyl acetate, filtered and dried to give the title product as a light brown solid (50 mg , Four. Five%) . LC-MS retention time = 2.436 min; [M + H] + 342. ^ • H NMR (400 MHz, d6-DMSO) d 0.79 (t, 3H, J = 7.4 Hz), 1.01 (t, 3H, J = 7.2 Hz), 1.35 (m, 2H ), 2.12 (s, 3H), 2.39 (m, 2H), 3.13 (m, 2H), 3.25 (s, 2H), 3.65 (s, 2H), 7.02 (s, 2H), 7.2-7. 38 (m, 3H), 7.48 (s, 1H), 8.52 (t, 3H, J = 5. 4 Hz) This compound has activity A in the fluorescence polarization assay described below. The following compounds (Table 5) are made by the method of Example 197, replacing the appropriate amine with propylamine. The fourth column of Table 5 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 5
Example 235 Ethyl amide of 2-amino-4- [2,4-dichloro-5- (2-diethylamino-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid
Stage 1 l-Benzyloxy-2/4-dichloro-5-nitro-benzene
Potassium carbonate (12g, 87mmol) was added to a solution of 2,4-dichloro-5-nitrophenol (15.6g, 75mmol) in acetone. The benzyl bromide (9ml, 76mmol) was added and the suspension heated, oil bath temperature 75 ° C, for ~ 3hrs. The resulting suspension was allowed to cool and water (500ml) was added, the mixture was extracted with dichloromethane (2x200ml). The combined extracts were washed with aqueous sodium hydroxide (150ml, 2M), water (2x200ml) and saturated aqueous sodium chloride solution (150mol). The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid (21.5g, 96%) Rf 0.73 CH2C12 (SiO2) Step 2 5-Benzyloxy-2,4-dichloro-phenylamine
Iron powder (21g, 376mmol) was added to a suspension of nitrobenzene (21.5g, 72mmol) in acetic acid
(300ml) / water (150ml) and the mixture was heated, oil bath temperature 85 ° C, for ~ 90mins. The resulting suspension was filtered. The filtrate was allowed to cool, the water (750ml) was added and the mixture was extracted with dichloromethane (3xl50ml). The combined extracts were washed with aqueous sodium hydroxide (300ml, 2M), water (2x500ml) and saturated aqueous sodium chloride solution (200ml). The solution was dried over anhydrous sodium sulfate and concentrated to a pale brown solid (18.6g, 96%). Rf 0.57 CH2C12 (Si02) Stage 3 1-Benzyloxy-2,4-dichloro-5-iodo-benzene
Hydrochloric acid (60ml, 6M) was added to an aniline solution (16.2g, 60mmol) in acetic acid (240ml) and the resulting suspension was cooled (ice / water / salt). Aqueous sodium nitrate (4.8g, 69.5mmol in 40ml) was added slowly
(keeping the temperature <5 ° C). Upon completion of the addition the resulting solution was stirred for ~ 30mins. The resulting solution was emptied into a solution of potassium iodide (20g, 120mmol) and iodine
(4g, lßramol) in water (200ml), and the mixture was stirred for 90mins. The water (800ml) was added and the mixture was extracted with dichloromethane (3x250ml). The combined extracts were washed with aqueous sodium thiosulfate solution (2x15 Oml, 10%), aqueous sodium hydroxide.
(250ml, 2M), water (2x250ml) and saturated aqueous sodium chloride solution (200ml). The solution was dried over anhydrous sodium sulfate and concentrated to a pale brown oil, solidified at rest (20.6g, 90%). Rf 0.82 CH2C12 (SiOa) Step 4 2-Amino-4- (5-benzyloxy-2,4-dichloro-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl ester
Potassium acetate (16g, 163mmol) was added to a solution of iodobenzene (20.6g, 54mmol) and bis (pinacolato) diboro
(14.5g, 57mmol) in DMF (50ml), under a nitrogen atmosphere. The palladium acetate (450 mg, cat.) Was added and the mixture was heated, oil bath temperature 90 ° C, for ~ 18 hrs. The resulting solution was concentrated and the residue was taken up in ethyl acetate (200ml), the solution was washed with water (3x200ml) and saturated aqueous sodium chloride solution (150ml). The solution was dried over anhydrous sodium sulfate and concentrated to a pale brown gum. The residue was taken in 1,4-dioxan (160ml) and 2-amino-4-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl ester.
(12.85g, 50mmol) and aqueous potassium phosphate (40ml, 2M) was added, under a nitrogen atmosphere. The dichloro bis (triphenylphosphine) palladium (II) (cat.) Was added and the mixture was heated, temperature of the oil bath 100 ° C, for ~ 3hrs. The mixture was allowed to cool and ethyl acetate (400ml) was added. The mixture was washed with saturated aqueous sodium chloride solution (100 ml). The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid. The solids were washed with diethyl ether / hexane (1: 1), to give an opaque white solid. It was dried in vacuo (40 ° C). 10.7g (45%) Rf 0.13 EtOAc / Hex (1: 3) (SiO2) LC retention time 2891 min [M + H] + 474.1 / 476. 1 (run time 3.75 min).
Stage 5 2-amino-4- (2,4-dichloro-5-hydroxy-phenyl) thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl amide
A suspension of ethyl ester of 2-amino-4- (5-benzyloxy-2,4-dichlorophenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid methylamine (-2M) was heated, ~ 75 ° C, during ~ 18hrs. The resulting solution was concentrated and the residue was triturated with diethyl ether / hexane to give a pale brown powder. CL retention time 2654 minutes [M + H] + 475.1 / 473.1 (Running time 3.75 minutes) To the solution of boron trichloride (1 M in dichloromethane) was added to a suspension of 2-amino acid ethyl amide. 4- (5-benzyloxy-2,4-dichlorophenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid in dichloromethane at -78 ° C under a nitrogen atmosphere. The suspension was stirred for ~ 3hrs at room temperature. The suspension was cooled in ice and methanol was added, the resulting mixture was stirred for 1 hr. and concentrated to a yellow-green solid. The solids were suspended in aqueous sodium acetate (10%) and extracted with ethyl acetate. The extracts were washed with water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a pale brown solid, washed with hexane, dried in vacuo. CL holding time 2180 minutes [M + H] + 385/383 (Run time 3.75mins).
Step 6: 2-Amino-4- [2,4-dichloro-5- (2-diethylamino-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl amide
The cesium carbonate was added to a solution of 2-amino-4- (2,4-dichloro-5-hydroxyphenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl amide in DMF, 2-Bromo-N, N-diethylethylamine hydrobromide was added and the suspension was heated to ~ 140 ° C for ~ 2hrs. The resulting suspension was allowed to cool and dichloromethane was added. The mixture was washed with water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a dark brown gum. The crude product was purified by chromatography on silica eluting with mixtures of dichloromethane and methanol.
XH NMR (400 MHz, d6-DMSO) d 0.96 (t, 6H, J = 7.1 Hz), 1.07 (t, 3H, J = 7.2 Hz), 2.55 (q, 4H, J = 7.1 Hz), 2.81 (t , 2H, J = 5.8 Hz), 3.22 (m, 2H), 4.12 (t, 2H, J = 5.8 Hz), 7.23 (s, 2H), 7.38 (s, 1 H), 7.57 (s, 1 H) , 7.80 (s, 1 H), 8.54 (t, 1H, J = 5.5 Hz). CL retention time 1774 minutes [M + H] + 484/482 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below.
Example 236 Ethyl amide of 2-amino-4- [2,4-dichloro-5- (2-morpholin-4-yl-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid
Step 1: 2-Amino-4- [2,4-dichloro-5- (2,2-diethoxy-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl amide
Potassium tert-butoxide was added to a suspension of 2-amino-4- (2,4-dichloro-5-hydroxyphenyl) -thieno [2,3-d] irimidine-6-carboxylic acid ethyl amide in acetonitrile. , bromoacetaldehyde diethyl acetal was added and the suspension was heated under reflux for ~ 8hrs. The resulting suspension was allowed to cool and water was added, the mixture was extracted with ethyl acetate and the extracts were washed with water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a red / brown gum. The crude product was purified by chromatography on silica eluting with mixtures of ethyl acetate and hexane. CL retention time 2614 minutes [M + H] + 501/499 (Run time 3.75mins).
Step 2: 2-Amino-4- [2,4-dichloro-5- (2-morpholin-4-yl-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid ethyl amide Hydrochloric acid was added to a solution of 2-amino-4- (2,4-dichloro-5- (2,2-diethoxyethoxy) -phenyl) -thieno [2,3-d] pyrimidine-ethyl 2-amide solution. -carboxylic acid in THF and the solution was stirred for ~ 18hrs. The morpholine was added and the solution was stirred, sodium triacetoxyborohydride was added and the resulting suspension was stirred for 118 hrs. The dichloromethane was added and the mixture was washed with aqueous ammonium (0.880), water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid. The crude product was purified by chromatography on silica eluting with mixtures of ethyl acetate and hexane. CL retention time 1,795 minutes [M + H] + 498/496 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below.
EXAMPLE 237 2-Amino-4- [2,4-dichloro-5- (2-diethylamino-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropyl amide
Step 1: 2-Amino-4- (5-benzyloxy-2,4-dichloro-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
Sodium hydroxide (0.190 g, 4.75 mmol) was added to ethyl ester of 2-amino-4- (5-benzyloxy-2,4-dichloro-phenyl) -thieno [2,3-d] pyrimidine- 6-carboxylic acid (step 4, example 235). Ethanol (25 ml) was added followed by water (2.5 ml) and the reaction mixture was heated to reflux for 1 hour. The reaction mixture was allowed to cool and the solvents were removed in vacuo. The resulting residue was dissolved in water and stirred in an ice-water bath and neutralized by the dropwise addition of a 37% hydrochloric acid (aqueous) solution. The reaction mixture was dried by freezing to give the product as a yellow powder (containing 2 equivalents of NaCl) 1.33 g; 100% CL holding time 2,579 minutes [M + H] + 448/446 (Run time 3.75mins).
Stage 2 2-Amino-4- (5-benzyloxy-2,4-dichloro-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropamide
0- (7-Azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (1176 g, 3.07 mmol) was added to 2-amino-4- (5-benzyloxy-2) acid , 4-dichloro-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid .2NaCl (1.33 g, 2.38 mmol) then DMF (25 mL) was added to give a cloudy brown solution. Isopropyl amine (1.01 ml); 11.9 mmol) was added and the reaction mixture was heated to 60 ° C (oil bath temperature) for 18 hours. The reaction mixture was allowed to cool to room temperature and DMF was removed in vacuo. The residue was partitioned between ethyl acetate (200 ml) and water (200 ml). The phases were separated and the organic phase was washed with saturated aqueous sodium chloride solution (200 ml), dried over anhydrous sodium sulfate, filtered and the filtered solvents were removed in vacuo to give a yellow solid. The crude product was purified by flash chromatography on silica gel (cartridge 50g IST Flash Si) eluting with a solvent gradient of 20 to 50% ethyl acetate in hexane. This gives the product as a colorless solid (0.612 g, 53%). CL holding time 2756 minutes [M + H] + 489/487 (Run time 3.75mins).
Stage 3 2-Amino-4- (2,4-dichloro-5-hydroxy-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropylamide
Prepared as per step 5 example 235 of 2-amino-4- (5-benzyloxy-2,4-dichloro-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropylamide (0.594 g) . The product was purified by flash chromatography on silica gel (20 g IST Flash Si cartridge) eluting with a solvent gradient of 20 to 100% ethyl acetate in hexane. This gives the product as a colorless solid (0.350 g, 72%). CL retention time 2353 minutes [M + H] + 399/397 (Run time 3.75mins).
2-amino-4- [2 # 4-dichloro-5- (2-diethylamino-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropyl amide
Prepared as per step 6 of Example 235 of 2-amino-4- (2,4-dichloro-5-hydroxy-phenyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid isopropylamide (0.100 g) ). The product was purified by preparative HPLC. CL holding time 1965 minutes [M + H] + 498/496 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below. The following compounds (Table 6) were made using the methods of Examples 235, 236 and 237. The fourth column of Table 6 establishes the activity of the compound in the fluorescence polarization assay described below.
Table 6
Example 272 2-Amino-4- [2,4-dichloro-5- (2-hydroxy-ethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
The hydrochloric acid was added to a solution of 2-amino-4 - (2,4-dichloro-5- (2,2-diethyethoxy) -phenyl) -thieno [2,3-d] pyrimidine-ethyl-2-amide. 6-carboxylic acid in THF and the solution was stirred for
~ 18hrs. The dichloromethane was added and the mixture was stirred, the sodium borohydride was added and the resulting suspension was stirred for ~5hrs. The dichloromethane was added and the mixture was washed with saturated ammonium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid. The crude product was purified by preparative HPLC, to give the product as an opaque white solid. CL holding time 2.124 minutes [M + H] + 428.9 / 426 (Run time 3.75mins).
Example 273 2-Amino-4- [2,4-dichloro-5- (1-methyl-piperidin-2-ylmethoxy) -phenyl] -thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
To the mixture of 2-amino-4- (2,4-di chloro-5-hydroxy-phenyl) -thieno [2, 3d] pyrimidine-6-carboxylic acid ethylamide (30 mg, 0.08 mmol) and (1- Methyl-piperidin-2-yl) -methanol (12 mg, 0.09 mmol) in dry tetrahydrofuran (10 ml) was added triphenylphosphine. (33 mg, 0.13 mmol). The diethylazodicarboxylate (0.021 ml, 0.13 mmol) in dry tetrahydrofuran (1 ml) was added dropwise during the space of 30 seconds at room temperature. The mixture was then stirred at room temperature for 30 minutes at which time ethyl acetate (30 ml) was added and the resulting solution was washed with 1M sodium bicarbonate solution (30 ml), followed by saturated brine (30 ml). . The resulting organics were dried with sodium sulfate and concentrated to give a yellow oil which was purified by preparative LCMS to give a white solid (20.4 mg, 53%). CL retention time 1.84 minutes, [M + H] + 494. This compound has activity A in the fluorescence polarization assay described below.
Example 274
2-Amino-4- (2,4-dimethyl-phenyl) thieno [2,3-d] pyrimidine-6-sulfonic acid cyclopropylamide
Stage 1 2-amino-4-chloro-6- (2,4-dimethyl-phenyl) -pyrimidine-5-carbaldehyde
The aqueous potassium phosphate was added to a suspension of 2,4-dimethylbenzene boronic acid and 2-amino-4,6-dichloro-5-pyrimidinecarbaldehyde (3 eq) in
1,4-dioxane, under a nitrogen atmosphere. Dichlorobis (triphenylphosphine) palladium (II) (cat.) Was added and the mixture was heated, ~ 100 ° C, for ~90mins. The resulting mixture was allowed to cool and dichloromethane was added, the mixture was washed with water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid. The crude solid was purified by column chromatography on silica eluting with the mixtures of diethyl ether and hexane. CL retention time 2.354 minutes [M + H] + 262.0 (Run time 3.75mins).
Step 2 2 -amino-4- (2,4-dimethyl-phenyl) -β-mercapto-pyrimidine-S-carbaldehyde
The 2-amino-4-chloro-6- (2,4-dimethylphenyl) -pyrimidine-5-carbaldehyde was added to a suspension of sodium sulphide (5eq.) In DMF and the mixture was stirred for ~ 60mins, Give a yellow suspension. The suspension was poured into water, and the solution was filtered. The filtrate was acidified with acetic acid, to give a yellow precipitate. The solids were removed by filtration and washed with water and hexane, dried in vacuo, to give a yellow powder. CL retention time 2048 minutes [M + H] + 260.0 (Run time 3.75mins). Step 3 C- [2-amino-6- (2,4-dimethyl-phenyl) -5-formyl-pyrimidin-4-ylsulfanyl] -N-cyclopropyl-methanesulfonamide
The sodium acid carbonate was added to a solution of 2-amino-4- (2,4-dimethylphenyl) -6-mercapto-pyrimidine-5-carbaldehyde in DMF and the suspension was stirred. The sulfonamide of C-bromo-N-cyclopropyl-methane was added, and the mixture was heated, ~ 85 ° C, for ~ 3hrs. The resulting suspension was allowed to cool and ethyl acetate was added, the mixture was washed with water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a pale yellow solid. The crude solid was purified by column chromatography on silica eluting with the mixtures of ethyl acetate and hexane. CL retention time 2413 minutes [M + H] + 393.0 (Run time 3.75mins) Step 4 2-Amino-4- (2,4-dimethyl-phenyl) -thieno [2,3-d] pyrimidine acid cyclopropylamide -6-sulfdnico
The pyridine was added to a sulfonamide suspension of C- [2-amino-6- (2, -dimethylphenyl) -5-formyl-pyrimidin-4-ylsulfanyl] -N-cyclopropyl-methane in dichloromethane and the mixture was cooled , ice water. The trifluoroacetic anhydride was added and the mixture was stirred for ~ 2 hrs and heated under reflux for ~ 24 hrs. The resulting dark red solution was allowed to cool and aqueous ammonium (0.880) was added and the mixture was stirred for ~30mins. The dichloromethane was added and the mixture was washed with dilute hydrochloric acid, water and saturated aqueous sodium chloride solution. The solution was dried over anhydrous sodium sulfate and concentrated to a red / orange solid. The crude solid was purified by preparative HPLC. ? E NMR (400 MHz, de-DMS0) d 0.40-0.45 (m, 2H), 0.50-0.55 (m,
2H), 2.22 (s, 3H), 2.27 (m, 1H), 2.36 (s, 3H), 7.17
(bd, 1H, J = 7.6 Hz), 7.18 (s, 1H), 7.21 (bs, 1H),
7. 28 (d, 1H, J = 7.6 Hz), 7.34 (s, 2H), 8.16 (bs, 1H). CL holding time 2478 minutes [M + H] + 375.0 (Run time 3.75mins). This compound has activity A in the fluorescent polarization assay described below. Example 275 Ethyl ester of 2-amino-4-phenethyl-thieno [2,3-d] pyridin-6-carboxylic acid
Stage 1 Ethyl ester of 2-amino-4-styryl-thieno [2,3-d] pyrimidine-6-carboxylic acid
To a solution of 2-amino-4-chlorotiene [2,3-d] pyrimidine-6-carboxylic acid ethyl ester (0.193g, 0.75trr. L.) And alpha-phenyl vinyl boronic acid (0.17g, 1.5 equiv. ) in DF at room temperature was added a solution of 1M sodium acid carbonate (1.88 ml, 2.5 equiv.) followed by bis (triphenylphosphine) palladium (II) chloride (26 mg, 0.05 equiv.). Nitrogen was bubbled through the mixture for 5 minutes before heating to 85 ° C and stirred for 10 hours. The cold solution was partitioned between ethyl acetate and water, the combined organics were washed with water and brine before being loaded directly onto an isolute SCX II ion exchange column. On elution with 1M ammonium in methanol and evaporation in vacuo, the pure product was recovered as an orange powder (0.169g, 70%). ^ H NMR (CDC13) d = 8.03 (1H, s); 8.03 (1H, d, J = 15Hz); 7.59 (2H, m); 7.41-7.30 (4H, m); 5.19 (2H, broad s); 4.31 (2H, q, J = 7.1 Hz) and 1.35 (3H, t, J = 7.1 Hz). CLEM holding time 7.47 mins, [M + H] + = 326.12 (run time 15 minutes).
This compound has A 'activity in the fluorescent polarization assay described below. Stage 2 Ethyl ester of 2-amino-4-phenethyl-thieno [2,3-d] pir: imidine-6-carboxylic acid
To a solution of the ethyl ester of 2-amino-4-styryl-thieno [2,3-d] pyrimidine-6-carboxylic acid ester (78 mg, O.ldmmol) in ethanol was added palladium in 5% charcoal ( 51 mg) which was stirred overnight under a hydrogen atmosphere. The suspension was filtered through celite, the volatiles were removed in vacuo and the residue was purified using semi-preparative HPLC to provide the pure compound as an orange powder. X H NMR (CDC13) d = 7.82 (1 H, s); 7.35-7.11 (5H, m); 5.33 (2H, broad s); 4.40 (2H, q, J = 7.1 Hz); 3.26 (2H, m); 3.22 (2H, m) and 1.43 (3H, t, J = 7.1 Hz). CLEM holding time 7.11 mins, [M + H] + = 327.92 (run time 15 minutes). This compound has activity "A" in the fluorescent polarization assay described below.
The following compounds (Table 7) are made by the methods of Example 275 substituting the appropriate boronic acid or boronate ester. The corresponding amides were synthesized directly from the ester (example 235, step 5) or by hydrolysis (example 43, step 1) followed by amine coupling (eg 43, step 2) and purified by semi-semi-preparative HPLC. The fourth column of Table 7 establishes the activity of the compound in the fluorescent polarization assay described below. Table 7
Hsp90 FP Comment
Example Structure MH + of synthesis IC50
279 356.1 Suzuki
280 360.0 Suzuki
281 360.1 Suzuki
282 344.2 Suzuki
Suzuki,
283 325.1 hydrolyze, then amidation
Example 294 Ester. of ethyl 2-amino-4- (lH-indol-3-yl) -thieno [2,3-d] irimidine-6-carboxylic acid
Stage 1 Ethyl ester of 2-amino-4- (1-benzenesulfonyl-lH-indol-3-yl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
Using 1- (phenylsulfonyl) -3 -indole boronic acid and the method of Example 275 step 1, the desired product was synthesized as an orange solid (105g, 29%). LCMS retention time 7.72 min, [M + H] + = 478. (run time 15 mins).
Step 2: 2-Amino-4- (lH-indol-3-yl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
A solution of the ethyl ester of 2-amino-4- (1-benzenesulfonyl-1H-indol-3-yl) -thieno [2,3-d] pyrimidine-6-carboxylic acid ester (80 mg, 0.17 mmol) in ethanol ( 6ml) was heated to 65 ° C, 2M potassium hydroxide (0.25ml, 3 equiv.) Was added and stirred overnight. The water was added and the volatile was removed in vacuo. The solution was then neutralized and dried by freezing. LCMS retention time 5.72 min, [M + H] + = 311.07 (run time 15 minutes).
Step 3 Ethyl ester of 2-amino-4- (lH-indol-3-yl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
The crude 2-amino-4- (lH-indol-3-yl) -thieno [2,3-d] irimidine-6-carboxylic acid was dissolved in ethanol (2 ml) and concentrated sulfuric acid (5 drops) was added. . The solution was refluxed overnight before adding the water and the volatiles were removed in vacuo. The aqueous solution was partitioned with 1 M sodium hydrogen carbonate solution and ethyl acetate. The organics were combined, dried over sodium sulfate and evaporated to dryness. The pure compounds are obtained after preparative CCD as an opaque white colorless powder. X H NMR (d 6 -DMS0) d = 11.93 (1 H, broad s); 8.62 (1 H, d, J = 7.5 Hz); 8.43 (1H, s); 8.27 (1H, s); 7.53 (1H, d, J = 7.5 Hz); 7.27-7.15 (1H + 1H + 2H, m); 4.34 (2H, q, J = 7.1 Hz) and 1.34 (3H, t, J = 7.1 Hz). LCMS retention time 6.70 min, [M + H] + = 339.08 (run time 15 minutes). This compound has activity? B 'in the fluorescent polarization assay described below.
Example 294 2-Amino-4-benzyloxy-thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
Step 1: 2-Amino-4-benzyloxy-thieno [2,3-d] pyrimidine-6-carboxylic acid
A benzyl alcohol was added to a nitrogen-filled flask containing sodium hydride (0.5mmol, 60% in mineral oil) in anhydrous THF (5ml).
(0.5mmol). The suspension was stirred vigorously for 10 minutes until no more gas evolves before transferring to a microwave reaction tube containing 2-amino-4-chlorotiene-2-ethyl ester., 3-d] pyrimidine-6-carboxylic acid (0.129g, 0.5mmol). The sealed tube was heated to 90 ° C for 5 mins using 300W in a CEM microwave oven (BEWARE!). The reaction mixture was partitioned between DCM and water, the water layer was neutralized and evaporated to dry in vacuo to leave the pure product. LCMS retention time 6.35 min, [M + H] + = 301.93 (run time 15 minutes)
Stage 2 2-amino-4-benzyloxy-thieno [2,3-d] pyrimidine-6-carboxylic acid ethylamide
The amide was synthesized using the HATU coupling conditions given in Example 43, step 2 and purified by column chromatography. X H NMR (CDC13) d = 7.49 (1H, s); 7.39-7.25 (5H, m); 6.03 (1H, broad t, J = 5 Hz); 5.39 (2H, s); 5.15 (2H, broad s); 3.38 (2H, dq, J = 5.7 Hz and J = 7.2 Hz); 1.14 (3H, t, J = 7.2 Hz).
LCMS retention time 6.34 min, [M + H] + = 329.05 (run time 15 minutes). This compound has activity? B 'in the fluorescent polarization assay described below.
Example 295 Ethyl ester of 2-amino-4- (4-chloro-benzoyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
To a solution of 2-amino-4-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid (1 mol eq.), P-chlorobenzaldehyde (1 mol eq.) And 3-ethyl-1-bromide methyl-3H-imidazol-l-inio (0.3 mol eq.) in DMF at room temperature, sodium hydride (1.1 mol eq., 60% in mineral oil) was added. The solution turned dark immediately and was stirred for 3 hours during which it turned into an orange solution. This was filtered through a sintered glass funnel, brine was added and the resulting precipitate was filtered and dried. The resulting yellow solids were purified either by preparative CCD or preparative HPLC. X H NMR (ds-acetone) d = 8.11 (2H, d, J = 8.8 Hz);
8. 03 (1H, s); 7.57 (2H, d, J = 8.8 Hz); 6.86 (2H, s); 4.33 (2H, q, J = 7.0 Hz) and 1.34 (3H, t, J = 7.0 Hz). LCMS retention time 7.49 min, [M + H] + = 362.06
(run time 15 minutes). This compound has activity "A" in the fluorescent polarization assay described below. The following compounds (Table 8) are made by the method of Example 295 substituting the appropriate benzaldehyde. The fourth column of Table 8 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 8
Hsp90 FP Comment
Example Structure MH + of synthesis IC50
302 362.0 Aroilation
303 346.0 Aroilation
304 362.1 Aroilation
305 346.0 Aroilation
306 356.1 Aroilation
Example 315 Ethyl ester of 2-amino-4- (1-benzo [1,3] dioxol-5-yl-1-hydroxy-ethyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
The ethyl ester of 2-amino-4- (benzo [1,3] dioxol-5-carbonyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid (example 312) (lOOmg) was dissolved in THF Anhydrous under a nitrogen atmosphere before adding methyl magnesium bromide (solution 3. OM in diethyl ether, 5 equiv.). The solution was stirred at 40 ° C overnight before being partitioned between 10% aqueous ammonium chloride solution and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated to give the crude product which was purified by preparative CCD to give the desired compound as a yellow powder. X H NMR (de-acetone) d = 8.04 (1H, s); 6.94 (1H, d, J = 7.7 Hz); 6.91 (1H, s); 6.64 (1H, d, J = 7.7 Hz); 6.50 (2H, broad s); 5.81 (2H, s); 5.46 (1H, s); 4.17 (2H, q, J = 7.1 Hz); 1.81 (3H, s) and 1.19 (3H, t, J = 7.1 Hz). LCMS retention time 6.37 min, (elimination of H20 in LCMS) [M + H] + = 370.07 (run time 15 minutes). This compound has activity "A" in the fluorescent polarization assay described below. Example 316 Ethyl ester of 2-amino-4- (benzo [1,3] dioxol-5-yl-cyano-methyl) -thieno [2,3-d] pyrimidine-6-carboxylic acid
To a solution of the ethyl ester of 2-amino-chloro-tieno [2,3-d] pyrimidine-6-carboxylic acid (1 equiv.) And benzo [1,3] dioxol-5-yl-acetonitrile (1 mol eq.) in DMF at room temperature, sodium hydride (1.1 mol eq., 60% in mineral oil) was added. The mixture was stirred at this temperature overnight under argon. After this, it was diluted with brine and extracted with ethyl acetate. The combined organic portions were washed with brine and water and dried with sodium sulfate. After filtration and evaporation of the solvent, brown solids are obtained, which were purified either by preparative CCD or preparative HPLC. 1 H NMR (d6-acetone) d = 7.76 (1H, s); 6.84 (1H, d, J = 8.0 Hz); 6.56 (1H + 1H + 1H, m); 6.10 (1H, d, J = 1.0 Hz); 6.05 (1H, d, J = 1.0 Hz); 4.3? (2H, q, J = 7.0 Hz) and 1.30 (3H, t, J = 7.0 Hz). LCMS retention time 7.04 min, [M + H] + = 383.06 (run time 15 minutes). This compound has activity "A" in the fluorescent polarization assay described below. The following compounds (Table 9) are made by the method of Example 316 substituting the appropriate acetonitrile. The fourth column of Table 9 establishes the activity of the compound in the fluorescent polarization assay described below.
Table 9
Example 319 Ethyl ester of 2-amino-4-cyano-thieno [2,3-d] pyrimidine-6-carboxylic acid
The ethyl ester of 2-amino-4-chloro-thieno [2,3-d] pyrimidine-6-carboxylic acid (1 equiv.), Zn (CN) 2 (0.6 equiv.), Zn powder (0.12 equiv.) .), Pd2 (dba) 3 (0.02 mol eq.) And 1,1 '-bis (diphenylphosphino) ferrocene (0.04 equiv.) Were mixed in DMA and the mixture was stirred under argon at 120 ° C for 24 hours. The resulting suspension was filtered through a short column of Celite, the filtrate was diluted with brine and extracted with ethyl acetate. The organic layer was then washed with brine, water and dried over sodium sulfate. After evaporation of the solvent, the crude oil was purified by preparative CCD. X H NMR (d g -acetone) d = 7.92 (1 H, s); 7.08 (1H, s); 4.42 (2H, q, J = 7.0 Hz) and 1.40 (3H, t, J = 7.0 Hz). LCMS retention time 6.10 min [M + H] + = 249.04 (run time 15 minutes). This compound has activity "A" in the fluorescent polarization assay described below.
Fluorescence polarization assay Fluorescence polarization (also known as fluorescence anisotropy) measures the rotation of fluorescent species in solution, where the larger the more polarized molecule the fluorescence emission will be. When the fluorophore is excited with polarized light, the emitted light is also polarized. The molecular size is proportional to the polarization of the emission by fluorescence. The probe labeled by fluoroescein RBT0045864-FAM-
binds to HSP90 (HSP90 from the N-terminal domain or full length human, full-length yeast) and anisotropy (probe rotation: protein complex) is measured. The test compound is added to the test plate, allowed to equilibrate and the anisotropy is measured again. Any change in anisotropy is due to competitive binding of the compound to HSP90 whereby the probe is released. Materials The chemicals are of the highest purity commercially available and all aqueous solutions are made in AR water. 1) Costar 96-well black test plate # 3915 2) Test buffer of (a) 100 mM Tris pH 7.4; (b) 20 mM KCl; (c) 6 mM MgCl2. Stored at room temperature 3) BSA (bovine serum albumin) 10 mg / ml (New England Biolabs # B9001S) 4) 20 mM probe in a stock concentration of 100% DMSO. Stored in the dark at room temperature. The working concentration of 200 nM diluted in RA water and stored at 4 ° C. The final concentration in the 80 nM assay. 5) Human full length HSP90 protein expressed in E. coli, purified > 95% (see, for example,
Panaretou et al., 1998) and stored in aliquots of
50 μL at -80 ° C. Protocol 1) Add 100 μl of Ix buffer to the HA and 12A pellets (= FP BLNK) 2) Prepare the test mixture - all reagents are kept on ice with a lid in the cuvette since the probe is sensitive to the light
i. Final concentration
Ix Hsp90 FP buffer solution 10 ml lx
BSA lOmg / ml (NEB) 5.0 μl 5 μg / ml
Probe 200 μM 4.0 μl 80 nM
Full length human Hsp90 6.25 μl 200 nM 3) Assay mix 100 μl aliquot to all other wells. 4) Seal the plate and leave in the dark at room temperature for 20 minutes to balance
Compound dilution plate - 1 x 3 dilution series
1) In a transparent 96-well v-bottom plate - (# VWR 007/008/257) add 10 μl 100% DMSO to wells Bl to Hll. 2) For the Al a All wells add 17.5 μl 100% DMSO
3) Add 2.5 μl cpd to Al. This gives 2.5 mM (50x) of reserve compound, assuming 20 mM compounds. 4) Repeat for wells A2 to A10. Control in columns 11 and 12. 5) Transfer 5 μl from row A to row B, not column 12. Mix well. 6) Transfer 5 μl from row B to row C. Mix well. 7) Repeat for row G. 8) Do not add any compound to row H, this is row zero. 9) This produces a 1 x 3 dilution series from 50 μM to 0.07 μM. 10) In well B12 prepare 20 μl of a standard compound 100 μM. 11) After the first incubation, the assay plate is read on a Fusion ™ -FP plate reader (Packard
BioScience, Pangbourne, Berkshire, UK). 12) After the first reading, 12 μl of diluted compound is added to each well for columns 1 to 10. In column 11 (standard curve is provided) only add compound Bll-Hll.
Add 2 μl of the standard 100 mM compound to the wells B12 - H12 (it is the positive control) 13) The Z 'factor is calculated from the zero controls and the positive wells. Typically gives a value of 0.7-0.9
The compounds tested in the above test were assigned to one of 2 activity ranges in particular A = < 10 μM; B = > 10 μM, and those assignments are reported previously. A growth inhibition assay was also employed for the evaluation of the candidate HSP90 inhibitors:
Evaluation of the cytotoxicity of the Solforhodamine B (SRB) assay: calculation of 50% inhibitory concentration (IC50).
Day 1 1) Determine the number of cells by the hemocytometer ..
2) When using an 8-channel multipipette, add 160 μl of the cell suspension (3600 cells / well or 2 x 104 cells / ml) to each well of a 96-well microtiter plate. 3) Incubate overnight at 37 ° C in a C0 incubator.
Day 2 4) Drug reserve solutions are prepared, and serial dilutions of each drug are carried out in a medium to give final concentrations in the wells. 5) Using a multiple pipette, 40 μl of drug (at a final concentration 5 x) is added to the wells in quadruplicate. 6) The control wells are on either side of the 96-well plates, where 40 μl of the medium is added. 7) Incubate the plates in a C02 incubator for 4 days (48 hours).
Day 6 8) remove the tip medium in the sink and slowly submerge the plate in ice cold 10% trichloroacetic acid (TCA). Leave for about 30 minutes on ice. 9) Wash the plates in tap water 3 times by immersing the plates in water baths of the tap and removing the tip. 10) Dry in an incubator. 11) Add 100 μl of 0.4% SRB in 1% acetic acid to each well (except the last row (right side) of the 96-well plate, this is the 0% control, ie without drug, without staining. The first row will be 100% control without drug but with staining). Leave for 15 minutes.
12) Thoroughly wash the SRB stain without binding with 4 washes of 1% acetic acid. 13) Dry the plates in an incubator. 14) Solubilize SRB using 100 μl of 10 mM Tris base and place the plates on a shake plate for 5 minutes. 15) Determine the absorbance at 540 nm using a plate reader. Calculate the mean absorbance for the wells in quadruplicate and express it as a percentage of the value for the control of the untreated wells. 16) Graph the values of. percentage of absorbance against logarithmic concentration of the drug and determine the IC50.
By way of illustration, the compound of Example 2 gave an IC50 in the 'A' range (< 50 uM) for the SRB growth suspension assay.
REFERENCES A number of publications are cited above in order to more fully describe the invention and the state of the art to which the invention pertains.
Complete citations for these references are provided below. Each of these references is incorporated herein by reference in its entirety in the present disclosure. Argon Y and Simen BB. 1999"Grp94, an ER chaperone with protein and peptide binding properties", Semin. Cell Dev. Biol., Vol. 10, pp.
495-505. Bij lmakers M- JJE, Marsh M. 2000"Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p561ck", Molecular Biology of the Cell, Vol. 11 (5), pp.
1585- 1595. Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000"Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti -inflammatory effects and interactions with glucocorticoid receptor in vivo", Brit. J. Pharmacol., Vol 131 (1), pp. 13- 16. Chen C-F, Chen Y, Dai KD, Chen P-L, Riley DJ and
Lee W-H. 1996"A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock", Mol. Cell. Biol., Vol. 16, pp. 4691-4699. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lozenzino L and Rosen N. 2001"A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiat ion of breast cancer cells ", Chem. Biol., Vol. 8, pp. 289-299. Conroy SE and Latchman DS. 1996"Do heat shock proteins have a role in breast cancer?", Brit. J. Cancer, Vol. 74, p. 717-721. Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB and Toft DO. 2000"The HSP90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J. Biol. Chem., Vol. 5, p. 3305-3312.
Fuller W, Cuthbert A. 2000"Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) - molecular Chaperone complex with geldanamycin stabilizes delta F508 CFTR in the rabbit reticulocyte lysate", J. Biol. Chem .; Vol 275 (48), pp. 37462-37468. Hickey E, Brandon SE, Smale G, Lloyd D and eber LA. 1999"Sequence and regulation of a gene encoding a human 89 -kilodal ton heat shock protein", Mol. Cell. Biol., Vol. 9, pp. 2615-2626. Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron SK, Wu C and Roy-Burman P. 2000"A novel association between the human heat shock transcription factor I (HSF1) and prostate adenocarcinoma, Am. J. Pathol., Vol. 156, pp. 857-864, Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA, 2001"Inhibition of signal transduction by the HSP90 inhibitor 17 -allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis ", Cancer Res., Vol. 61, pp. 4003-4009, Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ,
Choi Y, Kim DK, Lee M-0, Park H. 2002"Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-la / aryl hydrocarbon nuclear receptor translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol ", Mol. Pharmacol., Vol 62 (5), pp. 975-982. Hutter etal, 1996, Circulation, Vol. 94, pp. 1408. Jameel A, Skilton RA, Campbell TA, Chander SK, RC Coombes and Luqmani YA. 1992"Clinical and biological significance of HSP89a in human breast cancer", Int. J. Cancer, Vol. 50, p. 409-415. Jolly C and Morimoto Rl. 2000"Role of the heat shock response and molecular chaperones in oncogenesis and cell death", J. Nati. Cancer Inst. , Vol. 92, pp. 1564-1572. Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsuj inata T, Shamma A and Monden M. 1999"Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus" , Cancer, Vol. 85, pp. 1649-1657. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap KR. 1993"Preclinical antitumour evaluation of bis-acetale-amino-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug", Cancer Research, Vol. 53, pp. 2581-2586. Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P. 1999"DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90", J. Nati. Cancer Inst. , Vol. 91, pp. 1940-1949. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001"A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1 a and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts ", Jap. J. Cancer Res., Vol 92 (12), 1342-1351. Kwon HJ, Yoshida M, Abe K, Horinouchi S and Bepple T. 1992"Radicicol, an agent inducing the reversal of the phentoype of src- transformed fibroblasts, Biosci., Biotechnol., Biochem., Vol. 56, pp. 538- 539. Lebeau J, Le Cholony C, Prosperi MT and Goubin G. 1991"Constitutive overexpression of 89 kDa heat shock protein gene in the HBL100 mammary cell line converted to tumorigenic phenotype by the EJ / T24 Harvey-ras oncogene", Oncogene, Vol. 6, pp. 1125-1132. Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers L. 2000a "The heat shock protein 90 antagonist novobiocin interactions with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone", J. Biol. Chem., Vol 275, pp. 37181-37186. Marcu MG, Schulte TW and Neckers L. 2000b "Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins", J. Nati. Cancer Inst. , Vol. 92, pp. 242-248. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, MacKay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB and Sager R. 2000"Linking gene expression patterns to therapeutic groups in breast cancer ", Cancer Res., Vol. 60, pp. 2232-2238. Neckers L, Schulte TW and Momnaaugh E. 1999"Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity", Invest. New Drugs, Vol. 17, pp. 361-373. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A and Rodman L. 1997"Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats", Proc. Am. Assoc. Cancer Res., Vol. 38, pp. 308. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1998"ATP binding and hydrolysis are essential to the function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17, pp. 4829-4836. Plumier etal, 1997, Cell. Stress Chap., Vol. 2, pp. 162 Pratt WB. 1997"The role of the HSP90-based chaperone system in signa! Transduction by nuclear receptors and receptors signaling via MAP kinase '", Annu. Rev. Pharmacol. Toxicol , Vol. 37, pp. 297-326. Prodromou C and Pearl LH. 2000a "Structure and in vivo function of HSP90", Curr. Opin. Struct. Biol., Vol. 10, pp. 46-51. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1997"Identification and structural characterization of the ATP / ADP-binding site in the HSP90 molecular chaperone", Cell, Vol. 90, pp. 65-75.
Prodromou C, Panaretou B, Chohan S, Siligardi G,
O'Brien R, Ladbury JE, Roe SM, Piper PW and Pearl LH.
2000b "The ATPase cycle of HSP90 drives to molecular 'clamp' via transient dimerization of the N-terminal domains", EMBO J., Vol. 19, pp. 4383-4392. Rajder et al, 2000, Ann. Neurol., Vol. 47, pp. 782. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1999"Structural basis for inhibition of the HSP90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin", J. Med. Chem., Vol. 42, p. 260-266. Rutherford SL and Lindquist 'S. 1998"HSP90 as a capacitor for morphological evolution, Nature, Vol. 396, pp. 336-342, Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma SV 1999. "Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones", Mol.Endocrinologv, Vol. 13, pp. 1435-1448 Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft D and Neckers LM 1998. "Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamcyin", Cell Stress and Chaperones, Vol. 3, pp. 100-108 Schulte TW and Neckers LM 1998"The benzoquinone ansamycin 17 -allylamino- 17 -deemthoxygeldanamcyin binds to HSP90 and shares important biologic-activities with geldanamycin", Cancer Chemother, Pharmacol., Vol. 42, P. 273-279, Sittler et al, 2001, Hum Mol. Genet., Vol. 10, pp. 1307.
Smith DF 2001"Chaperones in signal transduction", in: Molecular chaperones in the cell (P Lund, ed., Oxford University Press, Oxford and NY), pp. 165-178. Smith DF, Whitesell L and Katsanis E. 1998"Molecular chaperones: Biology and prospects for pharmacological intervention", Pharmacological Reviews, Vol. 50, pp. 493-513. Song HY, Dunbar JD, Zhang YX, Guo D and Donner DB. 1995"Identification of a protein with homology to hsp90 that binds the type 1 tumor receptor necrosis", J. Biol. Chem., Vol. 270, p. 3574-3581. Stebbins CE, Russo A, Schneider C, Rosen N, Hartl
FU and Pavletich NP. 1997"Crystal structure of an HSP90-geldanamcyin complex: targeting of a protein chaperone by an antitumor agent", Cell, Vol. 89, pp.
239-250. Supko JG, Hickman RL, Grever MR and Malspeis L. 1995"Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent", Cancer Chemother. Pharmacol., Vol. 36, pp. 305-315. Tratzelt etal, 1995, Proc. Nat. Acad. Sci., Vol. 92, pp. 2944. Trost et al, 1998, J. Clin. Invest., Vol. 101, pp. 855
Tytell M and Hooper P. 2001"Heat shock proteins: new keys to the development of cytoprotective therapies", Emerging Therapeutic Taraets, Vol. 5, pp. 267-287. Uehara U, Hori M, Takeuchi T and Umezawa H. 1986"Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus", Mol. Cell. Biol., Vol. 6, pp. 2198-2206. Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication. (Merck &Co., Inc., USA). Sun. Int. PCT (2002), WO 0207761 Winklhofer et al, 2001, J. Biol. Chem., Vol. 276, 45160. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM. 1994"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation", Proc. Nati Acad. Sci. U S A., Vol. 91, pp. 8324-8328. Yorgin et al. 2000"Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases", J. Immunol. , Vol 164 (6), pp. 2915-2923. Young JC, Moarefi I and Hartl FU. 2001"HSP90: a specialized but essential protein-folding tool", J. Cell. Biol., Vol. 154, pp. 267-273. Zhao JF, Nakano H and Sharma S. 1995"Suppression of RAS and MOS transformation by radicicol", Oncogene, Vol. 11, pp. 161-173. It is noted that with this date, the best method known to the applicant to carry out the practice of said invention, is that which is clear from the present description of the invention.
Claims (40)
1. - The use of a compound of the Formula (I), or a salt, N-oxide, hydrate, or solvate thereof in the preparation of a composition for the inhibition of HSP90 activity in vitro or in vivo: wherein R2 is a group of Formula (IA): - (Ar1) ^ (Alqx) p- (Z) r- (Alq
2) BQ (IA) wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alq1 and Alq2 are C2-C3 alkenylene radicals or optionally substituted divalent C3-C3 alkylene, m, p, rys are independently 0 or 1, Z is -O-, -S-, - (C = 0) -, - (C = S ) -, -S02-, - (C = 0) 0-, - C (= 0) NRA-, -C (= S) NRA-, -S02NRA-, -NRAC (= 0) -, -NRAS02-, or -NRA- wherein RA is hydrogen or Ci-Ce alkyl, and Q is hydrogen or a carbocyclic or heterocyclic-optionally substituted radical; R3 is hydrogen, an optional substituent, or an optionally substituted (C? -C3) alkyl, aryl or heteroaryl radical; and R is a carboxylic ester, carboxamide or sulfonamide group. 2. - A method of treating diseases that respond to the inhibition of HSP90 activity in mammals, the method characterized in that it comprises administering to the mammal an amount of the compound according to claim 1, effective to inhibit HSP90 activity.
3. The use according to claim 1 or method according to claim 1, for the immunosuppression or treatment of viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, type I diabetes, lupus, psoriasis. and inflammatory bowel disease; disease related to cystic fibrosis angiogenesis such as diabetic retinopathy, hemangiomas and endometriosis; or for the protection of normal cells against the toxicity induced by chemotherapy; or diseases where the failure to experience apoptosis is a fundamental factor; or protection from hypoxia-ischemic injury due to the elevation of Hsp70 in the heart and brain; cenurosis / CJD, Huntingdon or Alzheimer's disease.
4. The use in accordance with the claim 1, or the method in accordance with the claim 2, for the treatment of cancer.
5. The use or method according to any of the preceding claims, wherein, in the compound (I), m is 1, each of p, r and s is 0, and Q is hydrogen.
6. The use or method according to any of the preceding claims, wherein, in the compound (I), R2 is phenyl, 2 or 3-thienyl, 2 or 3-furanyl, 2, 3 or 4-pyridinyl, morpholinyl or optionally substituted piperidinyl.
7. The use or method according to claim 6, wherein, in the compound (I), R 2 is phenyl, optionally substituted by one or more substituents selected from methyl, ethyl, n- or isopropyl, vinyl, allyl, methoxy, ethoxy, n-propyloxy, benzyloxy, allyloxy, cyanomethoxy chlorine, bromine, cyano, formyl, methyl-, ethyl-, or n-propyl-carbonyloxy, methyl- or ethylaminocarbonyl, and substituents of the formula -0 (CH2) nZ1 in where n is 1, 2 or 3 and Z 1 is a primary, secondary, tertiary or cyclic amino group, or a C 1 -C 3 alkoxy group; or of the formula - (Alq3) mZ1 wherein Alq3 is a straight or branched divalent straight chain alkylene (Ci- C3), m is 0 or 1, and Z1 is a primary, secondary, tertiary or cyclic amino group, or a C6-C6 alkoxy group.
8. The use or method according to claim 7, wherein the optional substituents are in positions 2 and / or 4 and / or 5 of the phenyl ring.
9. The use or method according to any of the preceding claims, wherein, in the compound (I), m is 1, p, r and s are 0, and Q is an optionally substituted carbocyclic or heterocyclic ring.
10. The use or method according to any of the preceding claims, wherein, in the compound (I), Ar1 is a phenyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazinyl ring.
11. The use or method according to any of the preceding claims, wherein, in the compound (I), R3 is hydrogen.
12. The use or method according to any of the preceding claims, wherein in the compound (I) R4 is a carboxamide group of the formula -CONRB (Alq) nRA or a sulfonamide group of the formula -S02NRB (Alq) nRA in where Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical, n is 0 or 1, RB. is hydrogen or a C?-C6 alkyl or C2-C6 alkenyl group, hydroxy or carbocyclic RA or optionally substituted heterocyclyl, or RA and RB when taken together with the nitrogen to which they are bonded form an N-heterocyclic ring which may optionally be containing one or more additional heteroatoms selected from 0, S and N, and which may optionally be substituted on one or more C or N atoms in the ring.
13. The use or method according to claim 12, wherein Alq is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2CH = CH-, or -CH2CCCH2- optionally substituted, RB is hydrogen or methyl, ethyl, n- or iso-propyl, or allyl, hydroxy RA or optionally substituted phenyl, 3,4-methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl, or RA and RB when taken together with the nitrogen to which they bond they form an N-heterocyclic ring which may optionally contain one or more additional heteroatoms selected from 0, S and N, and which may optionally be substituted on one or more C or N atoms in the ring.
14. The use or method according to any of claims 1 to 11, wherein, in the compound (I) R4 is a carboxylic ester group of the formula -C00Rc wherein Rc is a C? -C6 alkyl group or a C2-C6 alkenyl, or an optionally substituted aryl or heteroaryl group, or an optionally substituted aryl (C? -C3) alkyl or heteroaryl (Ci-C6 alkyl) -alkyl group or an optionally substituted cycloalkyl group.
15. The use or method according to any of claims 1 to 11, wherein, in the compound (I) R4 is a carboxylic ester group of the formula -C00Rc wherein Rc is methyl, ethyl, n- or iso -propyl, allyl, phenyl, pyridyl, thiazolyl, benzyl, pyridylmethyl, cyclopentyl or optionally substituted cyclohexyl.
16. The use or method according to any of claims 1 to 4, wherein, the compound (I) has the formula (II) wherein A is a secondary amino group R10 is H, Cl, Br or CH3; Rii is hydrogen, Cl, Br, CN, methyl, ethyl, n- or isopropyl, vinyl or allyl; Ra2 is (i) a radical of the formula -IOCH-nZ1 wherein n is 1, 2 or 3 and Z1 is a primary, secondary, tertiary or cyclic amino group, or an alkoxy group Cr-Cs; or (ii) a radical of the formula - (Alk3) ^ 1 wherein Alk3 is a straight or branched chain divalent (C? -C3) alkylene, m is 0 or 1 and Z1 is a primary, secondary, tertiary amino group or cyclic, or a Ci-Cg alkoxy group.
17. The use or method according to claim 16, wherein, in the compound (II), A is a secondary alkylaminoC? -C6 group.
18. The use or method according to claim 16 or claim 17, wherein, in the compound (II), R? 2 is (i) a radical of the formula -OÍCH ^ nZ1 wherein n is 1, 2 or 3 and Z1 is di (C? -C3 alkyl) amino or C? -C3 alkoxy.
19. A compound of the formula (I), or a salt, N-oxide, hydrate or solvate thereof: characterized in that R2 is a group of Formula (IA): - (Ar1) m- (Alq1) p- (Z) r- (Alq2) SQ (IA) wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alq1 and Alk2 are C2-C3 alkylene radicals or optionally substituted divalent C2-C3 alkenylene, m, p, rys are independently 0 or 1, Z is -O-, -S-, ~ (C = 0) -, - (C = S ) -, -S02-, C (= 0) 0-, -C (= 0) NRA-, -C (= S) NRA-, -S02NRA-, -NRAC (= 0) -, -NRAS02- or - NRA- wherein RA is hydrogen or C-? -C6 alkyl, and Q is hydrogen or an optionally substituted heterocyclic or carbocyclic radical; R3 is hydrogen, an optional substituent, or an optionally substituted aryl or heteroaryl (C? -C3) alkyl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group, with the proviso that (i) R3 is not -NH2 or (ii) when R4 is -COOCH3 and R3 is hydrogen then R2 is not NH2, ethylamino, diethylamino, phenylamino or -N (Ph) (C2H5) wherein Ph is phenyl, and (iii) when R4 is -CONH2 and R2 is hydrogen then R2 is not -NH2.
20. The compound according to claim 19, characterized in that R3 is hydrogen.
21. The compound according to claim 19 or claim 20, characterized in that m is 1, each of p, r and s is 0, and Q is hydrogen.
22. The compound according to claim 21, characterized in that R2 is phenyl, 2 or 3-thienyl, 2 or 3-furanyl, 2, 3 or 4-pyridinyl, morpholinyl or optionally substituted piperidinyl.
23. The compound according to claim 21, characterized in that R is phenyl, optionally substituted by methyl, ethyl, n- or isopropyl, vinyl, allyl, methoxy, ethoxy, n-propyloxy, benzyloxy, allyloxy, cyanomethoxy chlorine, bromine, cyano, formyl, methyl-, ethyl-, or n-propyl-carbonyloxy, methyl- or ethylaminocarbonyl.
24. The compound according to claim 23, characterized in that the optional substituents are in positions 2 and / or 4 and / or 5 of the phenyl ring.
25. The compound according to claim 19 or claim 20, characterized in that m is 1, and p, r and s are 0, and Q is an optionally substituted carbocyclic or heterocyclic ring.
26.- The compound in accordance with the claim 19 or claim 20, characterized in that m is 1 and at least one of p, r and s is 1.
27.- The compound according to any of claims 19 to 26, characterized in that Ar1 is an optionally substituted phenyl ring.
28. The compound according to claim 19 or claim 20, characterized in that it is 0.
29. The compound according to claim 26 or claim 27, characterized in that Alq1 when presented is -CH2-, -CH2. -CH2-, or -CH2CH = CH- optionally substituted; Alk2 when present is -CH2-, -CH2-CH2-, or -CH2CH = CH-optionally substituted; Z when presented is -O- or -NH-; and Q is hydrogen.
30. The compound according to claim 29, characterized in that Z and Alk2 are present, and Alk2 is substituted by di (C? -C3) alkyl amino or C? -C3 alkoxy.
31. The compound according to any of claims 19 to 30, characterized in that R4 is a carboxamide group of the formula -C0NRB (Alq) nRA or a sulfonamide group of the formula -S02NRB (Alq) nRA wherein Alq is a optionally substituted divalent alkylene, alkenylene or alkynylene radical, n is 0 or 1, RB is hydrogen or a C?-C6 alkyl or C2-C6 alkenyl group, RA is hydroxy or optionally substituted carbocyclic, for example hydroxy and / or phenyl substituted with chlorine and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl, any of which heterocyclic rings can be substituted, or RA and RB when taken together with the nitrogen to which they are bound form an N-heterocyclic ring which it may optionally contain one or more additional heteroatoms selected from O, S and N, and which may optionally be substituted on one or more C or N atoms in the ring.
32. The compound according to claim 31, characterized in that Alk is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2CH = CH-, or -CH2CCCH2- optionally substituted, RB is hydrogen or methyl , ethyl, n- or iso-propyl, or allyl, hydroxy RA or optionally substituted phenyl, 3,4-methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl, or RA and RB when taken together with nitrogen to which they are linked form an N-heterocyclic ring which may optionally contain one or more additional heteroatoms selected from O, S and N, and which may optionally be substituted on one or more C or N atoms in the ring.
33. The compound according to claim 31 or claim 32, characterized in that R4 is a carboxamide group.
34. The compound according to any of claims 19 to 30, characterized in that R is a carboxylic ester group of the formula -COORc wherein Rc is a C? -Ce alkyl group or a C2-C3 alkenyl group, or a group optionally substituted aryl or heteroaryl, or an optionally substituted aryl (C 1 -C 3) alkyl or heteroaryl (C 6 alkyl) group or an optionally substituted cycloalkyl group.
The compound according to any of claims 19 to 30, characterized in that R4 is a carboxylic ester group of the formula -COORc wherein Rc is methyl, ethyl, n- or iso-propyl, allyl, phenyl, pyridyl, optionally substituted thiazolyl, benzyl, pyridylmethyl, cyclopentyl or cyclohexyl.
36. - The compound according to claim 19, characterized in that it has the formula (II) wherein A is a secondary amino group Rio is H, Cl, Br or CH3; R n is hydrogen, Cl, Br, CN, methyl, ethyl, n- or isopropyl, vinyl or allyl; Ri2 is (i) a radical of the formula -0 (CH2) nZ1 wherein n is 1, 2 or 3 and Z1 is a primary, secondary, tertiary or cyclic amino group, or a C6-C6 alkoxy group; or (ii) a radical of the formula - (Alk3) mZ1 wherein Alq3 is a straight or branched chain divalent (C? -C3) alkylene, m is 0 or 1 and Z1 is a primary, secondary, tertiary or cyclic, or an alkoxyCi-Cg group.
37. The compound according to claim 36, characterized in that A is a secondary alkylaminoC? -C6 group. 38.- The compound in accordance with the claim36 or claim 37, characterized in that Ri2 is (i) a radical of the formula -O (CH2) nZ1 wherein n is 1, 2 or 3 and Z1 is di (C1-C3 alkyl) amino or C1-C3 alkoxy. 39.- The compound according to claim 38, characterized in that it is the subject of any of the Examples, except for Example 74. 40.- A pharmaceutical or veterinary composition, characterized in that it comprises the compound according to any of claims 19 to 39, together with one or more pharmaceutically acceptable carriers and / or excipients.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0320300.7 | 2003-08-29 | ||
GB0327924.7 | 2003-12-02 | ||
GB0414467.1 | 2004-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06002118A true MXPA06002118A (en) | 2006-12-13 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1675861B1 (en) | Pyrimidothiophene compounds | |
JP4891904B2 (en) | Pyrimidothiophene compound | |
US7803831B2 (en) | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | |
CN100455586C (en) | Pyrimidothiophene compounds | |
EP2007767B1 (en) | Pyrrolopyrimidine derivatives used as hsp90 inhibitors | |
US20090181989A1 (en) | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | |
US20110034457A1 (en) | Pyridothiophene Compounds | |
WO2006090094A1 (en) | Pyrimidothiophene compounds for use as hsp90 inhibitors | |
US20100010037A1 (en) | 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors | |
EP1851228A1 (en) | Pyrimidothiophene compounds having hsp90 inhibitory activity | |
MXPA06002118A (en) | Pyrimidothiophene compounds |